<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C5FD03BC-C39D-4084-B2FE-A38FB9177D1A"><gtr:id>C5FD03BC-C39D-4084-B2FE-A38FB9177D1A</gtr:id><gtr:name>National Institute of Health, Mozambique (Instituto Nacional de Sa?de)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9E6E29A1-FFE3-487C-84F6-02CD1B6E313A"><gtr:id>9E6E29A1-FFE3-487C-84F6-02CD1B6E313A</gtr:id><gtr:name>National Institute for Biological Standards and Control (NIBSC)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/75EF0AF5-F985-4959-A7EC-8E2C939BC376"><gtr:id>75EF0AF5-F985-4959-A7EC-8E2C939BC376</gtr:id><gtr:name>European AIDS Treatment Group (EATG)</gtr:name><gtr:address><gtr:line1>Raymond Blyckaertsplein 13</gtr:line1><gtr:line2>Place Raymond Blyckaerts 13</gtr:line2><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/BDB62FBC-921E-49FF-AD56-909ED429E427"><gtr:id>BDB62FBC-921E-49FF-AD56-909ED429E427</gtr:id><gtr:name>Institute of Tropical Medicine</gtr:name><gtr:address><gtr:line1>Nationalestraat 155</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/1F16F444-D5C0-4FB7-ADF1-5E95B4393DCE"><gtr:id>1F16F444-D5C0-4FB7-ADF1-5E95B4393DCE</gtr:id><gtr:name>IrsiCaixa Institute for AIDS Research</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/7A0397DD-E0C6-4EA3-8031-B841D2503C4D"><gtr:id>7A0397DD-E0C6-4EA3-8031-B841D2503C4D</gtr:id><gtr:name>Royal Holloway, University of London</gtr:name><gtr:address><gtr:line1>Egham Hill</gtr:line1><gtr:line4>Egham</gtr:line4><gtr:line5>Surrey</gtr:line5><gtr:postCode>TW20 0EX</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/DF930BA1-5D36-4AE0-AE42-08B4B2D37BFA"><gtr:id>DF930BA1-5D36-4AE0-AE42-08B4B2D37BFA</gtr:id><gtr:name>Pasteur Merieux Serums</gtr:name><gtr:address><gtr:line1>Mallards Reach</gtr:line1><gtr:line2>Bridge Avenue</gtr:line2><gtr:postCode>SL6 1QP</gtr:postCode><gtr:region>South East</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F7F8EA22-4A18-4B69-AA3D-A0E9C0B0EE7C"><gtr:id>F7F8EA22-4A18-4B69-AA3D-A0E9C0B0EE7C</gtr:id><gtr:name>ALTA</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9C687B40-4780-4290-A0E0-39EC669D33CF"><gtr:id>9C687B40-4780-4290-A0E0-39EC669D33CF</gtr:id><gtr:name>Muhimbili University of Health and Allied Sciences</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/48990B2D-6D88-4205-B3F4-58863EA78D0D"><gtr:id>48990B2D-6D88-4205-B3F4-58863EA78D0D</gtr:id><gtr:name>National Institute of Health and Medical Research (INSERM)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4D643118-D00D-43C5-A6C4-6035292F169C"><gtr:id>4D643118-D00D-43C5-A6C4-6035292F169C</gtr:id><gtr:name>Novartis</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C5A9884D-F4F2-4A19-9E24-1268191D0E05"><gtr:id>C5A9884D-F4F2-4A19-9E24-1268191D0E05</gtr:id><gtr:name>University of Siena</gtr:name><gtr:address><gtr:line1>Universita Delgi Studi Di Siena</gtr:line1><gtr:line2>Via Banchi di Sotto 55</gtr:line2><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/044FA7AC-2B61-47DD-BE3F-15E7411CA30C"><gtr:id>044FA7AC-2B61-47DD-BE3F-15E7411CA30C</gtr:id><gtr:name>University Hospital Centre Vaudois</gtr:name><gtr:address><gtr:line1>University Hospital Centre Vaudois</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/728636B0-61D3-4346-9055-309321344A27"><gtr:id>728636B0-61D3-4346-9055-309321344A27</gtr:id><gtr:name>Eurovacc Foundation</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/8AB5107C-18AB-4D38-8CFB-96AD4680EB3D"><gtr:id>8AB5107C-18AB-4D38-8CFB-96AD4680EB3D</gtr:id><gtr:name>UK HIV Vaccine Consortium (UKHVC)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/E37A18E2-1E33-4ACE-BCFA-7DAD0DAF1261"><gtr:id>E37A18E2-1E33-4ACE-BCFA-7DAD0DAF1261</gtr:id><gtr:name>University of Regensburg</gtr:name><gtr:address><gtr:line1>University of Regensburg</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Germany</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/1C4A24DC-2FF4-47B7-B5FA-46BFF24DF5AB"><gtr:id>1C4A24DC-2FF4-47B7-B5FA-46BFF24DF5AB</gtr:id><gtr:name>National Institute for Medical Research</gtr:name><gtr:address><gtr:line1>Ocean Road</gtr:line1><gtr:line2>PO Box 9653</gtr:line2><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C754D612-4D8B-42CB-922C-07E7F5BE4B49"><gtr:id>C754D612-4D8B-42CB-922C-07E7F5BE4B49</gtr:id><gtr:name>Washington University in St. Louis</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C7FBE408-C743-4AAC-9BC6-65E14BC8D2FD"><gtr:id>C7FBE408-C743-4AAC-9BC6-65E14BC8D2FD</gtr:id><gtr:name>Karolinska Institute</gtr:name><gtr:address><gtr:line1>Administration</gtr:line1><gtr:line4>Stockholm</gtr:line4><gtr:postCode>SE-171 77</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Sweden</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F325BF32-08AE-4621-8057-E5D6613B7308"><gtr:id>F325BF32-08AE-4621-8057-E5D6613B7308</gtr:id><gtr:name>St George's University of London</gtr:name><gtr:address><gtr:line1>Cranmer Terrace</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>SW17 0RE</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5A8AC1E5-EA82-42CC-9E91-F0294FBF578B"><gtr:id>5A8AC1E5-EA82-42CC-9E91-F0294FBF578B</gtr:id><gtr:name>Robert Koch Institute</gtr:name><gtr:address><gtr:line1>Robert Koch Institut</gtr:line1><gtr:line2>Nordufer 20</gtr:line2><gtr:line4>D-13353 Berlin-Wedding</gtr:line4><gtr:region>Outside UK</gtr:region><gtr:country>Germany</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/99A20F70-F6B7-43DE-94E4-7004FAE6291E"><gtr:id>99A20F70-F6B7-43DE-94E4-7004FAE6291E</gtr:id><gtr:name>Ludwig Maximilians University Munich</gtr:name><gtr:address><gtr:line1>Geschwister-Scholl-Platz 1</gtr:line1><gtr:postCode>D-80539</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/FC75162A-C4F8-497E-AD42-5EEF4C35E48A"><gtr:id>FC75162A-C4F8-497E-AD42-5EEF4C35E48A</gtr:id><gtr:name>Infectious Disease Research Institute (IDRI)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5C1114A7-CE62-4DEC-BB95-695D6E2666CF"><gtr:id>5C1114A7-CE62-4DEC-BB95-695D6E2666CF</gtr:id><gtr:name>University of Verona</gtr:name><gtr:address><gtr:line1>strada le Grazie 15</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/8319F78A-DCBD-49F6-BE00-78E1CD75CDA9"><gtr:id>8319F78A-DCBD-49F6-BE00-78E1CD75CDA9</gtr:id><gtr:name>University of York</gtr:name><gtr:address><gtr:line1>Heslington</gtr:line1><gtr:line4>York</gtr:line4><gtr:line5>North Yorkshire</gtr:line5><gtr:postCode>YO10 5DD</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/49C44558-A75A-448F-9BF7-3F947FA67EB7"><gtr:id>49C44558-A75A-448F-9BF7-3F947FA67EB7</gtr:id><gtr:name>Technical University of Munich</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/67B34D05-3A52-4A09-8FF9-F2398D60E246"><gtr:id>67B34D05-3A52-4A09-8FF9-F2398D60E246</gtr:id><gtr:name>University of Surrey</gtr:name><gtr:address><gtr:line1>Registry</gtr:line1><gtr:line2>Stag Hill</gtr:line2><gtr:line4>Guildford</gtr:line4><gtr:line5>Surrey</gtr:line5><gtr:postCode>GU2 7XH</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/39147180-4991-4D6E-A137-E473AB40A04E"><gtr:id>39147180-4991-4D6E-A137-E473AB40A04E</gtr:id><gtr:name>International AIDS Vaccine Initiative (IAVI)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/7BC6FCF2-358C-45C5-A5A7-E859DD754711"><gtr:id>7BC6FCF2-358C-45C5-A5A7-E859DD754711</gtr:id><gtr:name>Lund University</gtr:name><gtr:address><gtr:line1>Box 117</gtr:line1><gtr:line2>S-221 00</gtr:line2><gtr:line4>Lund</gtr:line4><gtr:postCode>S-221 00</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Sweden</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/51CEB9A4-EEF4-4BC5-9845-AEA1B45A3AF8"><gtr:id>51CEB9A4-EEF4-4BC5-9845-AEA1B45A3AF8</gtr:id><gtr:name>French National Agency for Research on AIDS and Viral Hepatitis (ANRS)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/680A2524-B8AD-4E19-ACD2-3EECFCC5DAF1"><gtr:id>680A2524-B8AD-4E19-ACD2-3EECFCC5DAF1</gtr:id><gtr:name>Hull York Medical School</gtr:name><gtr:address><gtr:line1>John Hughlings Jackson Building</gtr:line1><gtr:postCode>YO10 5DD</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/36FCE8DD-97CB-47E6-A1E8-AE17410DD826"><gtr:id>36FCE8DD-97CB-47E6-A1E8-AE17410DD826</gtr:id><gtr:name>Government of Sweden</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2E8E7A84-3BC7-4739-986D-C05FC31789B8"><gtr:id>2E8E7A84-3BC7-4739-986D-C05FC31789B8</gtr:id><gtr:name>Charit? - University of Medicine Berlin</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C7B2F79C-C794-4597-898F-93292A2B77A3"><gtr:id>C7B2F79C-C794-4597-898F-93292A2B77A3</gtr:id><gtr:name>Fit Biotech Oy</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/63E44D26-67E6-4BB1-B63E-E2730AE68EB0"><gtr:id>63E44D26-67E6-4BB1-B63E-E2730AE68EB0</gtr:id><gtr:name>Braunschweig University of Technology</gtr:name><gtr:address><gtr:line1>Mendelssohnstr</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Germany</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/666A7C6D-E59C-4C37-8997-490B93914C41"><gtr:id>666A7C6D-E59C-4C37-8997-490B93914C41</gtr:id><gtr:name>MRC Clinical Trials Unit</gtr:name><gtr:address><gtr:line1>Aviation House</gtr:line1><gtr:line2>125 Kingsway</gtr:line2><gtr:postCode>WC2B 6NH</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/666A7C6D-E59C-4C37-8997-490B93914C41"><gtr:id>666A7C6D-E59C-4C37-8997-490B93914C41</gtr:id><gtr:name>MRC Clinical Trials Unit</gtr:name><gtr:address><gtr:line1>Aviation House</gtr:line1><gtr:line2>125 Kingsway</gtr:line2><gtr:postCode>WC2B 6NH</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C5FD03BC-C39D-4084-B2FE-A38FB9177D1A"><gtr:id>C5FD03BC-C39D-4084-B2FE-A38FB9177D1A</gtr:id><gtr:name>National Institute of Health, Mozambique (Instituto Nacional de Sa?de)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9E6E29A1-FFE3-487C-84F6-02CD1B6E313A"><gtr:id>9E6E29A1-FFE3-487C-84F6-02CD1B6E313A</gtr:id><gtr:name>National Institute for Biological Standards and Control (NIBSC)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/75EF0AF5-F985-4959-A7EC-8E2C939BC376"><gtr:id>75EF0AF5-F985-4959-A7EC-8E2C939BC376</gtr:id><gtr:name>European AIDS Treatment Group (EATG)</gtr:name><gtr:address><gtr:line1>Raymond Blyckaertsplein 13</gtr:line1><gtr:line2>Place Raymond Blyckaerts 13</gtr:line2><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/BDB62FBC-921E-49FF-AD56-909ED429E427"><gtr:id>BDB62FBC-921E-49FF-AD56-909ED429E427</gtr:id><gtr:name>Institute of Tropical Medicine</gtr:name><gtr:address><gtr:line1>Nationalestraat 155</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/1F16F444-D5C0-4FB7-ADF1-5E95B4393DCE"><gtr:id>1F16F444-D5C0-4FB7-ADF1-5E95B4393DCE</gtr:id><gtr:name>IrsiCaixa Institute for AIDS Research</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/7A0397DD-E0C6-4EA3-8031-B841D2503C4D"><gtr:id>7A0397DD-E0C6-4EA3-8031-B841D2503C4D</gtr:id><gtr:name>Royal Holloway, University of London</gtr:name><gtr:address><gtr:line1>Egham Hill</gtr:line1><gtr:line4>Egham</gtr:line4><gtr:line5>Surrey</gtr:line5><gtr:postCode>TW20 0EX</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/DF930BA1-5D36-4AE0-AE42-08B4B2D37BFA"><gtr:id>DF930BA1-5D36-4AE0-AE42-08B4B2D37BFA</gtr:id><gtr:name>Pasteur Merieux Serums</gtr:name><gtr:address><gtr:line1>Mallards Reach</gtr:line1><gtr:line2>Bridge Avenue</gtr:line2><gtr:postCode>SL6 1QP</gtr:postCode><gtr:region>South East</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F7F8EA22-4A18-4B69-AA3D-A0E9C0B0EE7C"><gtr:id>F7F8EA22-4A18-4B69-AA3D-A0E9C0B0EE7C</gtr:id><gtr:name>ALTA</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9C687B40-4780-4290-A0E0-39EC669D33CF"><gtr:id>9C687B40-4780-4290-A0E0-39EC669D33CF</gtr:id><gtr:name>Muhimbili University of Health and Allied Sciences</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/48990B2D-6D88-4205-B3F4-58863EA78D0D"><gtr:id>48990B2D-6D88-4205-B3F4-58863EA78D0D</gtr:id><gtr:name>National Institute of Health and Medical Research (INSERM)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4D643118-D00D-43C5-A6C4-6035292F169C"><gtr:id>4D643118-D00D-43C5-A6C4-6035292F169C</gtr:id><gtr:name>Novartis</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C5A9884D-F4F2-4A19-9E24-1268191D0E05"><gtr:id>C5A9884D-F4F2-4A19-9E24-1268191D0E05</gtr:id><gtr:name>University of Siena</gtr:name><gtr:address><gtr:line1>Universita Delgi Studi Di Siena</gtr:line1><gtr:line2>Via Banchi di Sotto 55</gtr:line2><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/044FA7AC-2B61-47DD-BE3F-15E7411CA30C"><gtr:id>044FA7AC-2B61-47DD-BE3F-15E7411CA30C</gtr:id><gtr:name>University Hospital Centre Vaudois</gtr:name><gtr:address><gtr:line1>University Hospital Centre Vaudois</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/728636B0-61D3-4346-9055-309321344A27"><gtr:id>728636B0-61D3-4346-9055-309321344A27</gtr:id><gtr:name>Eurovacc Foundation</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/8AB5107C-18AB-4D38-8CFB-96AD4680EB3D"><gtr:id>8AB5107C-18AB-4D38-8CFB-96AD4680EB3D</gtr:id><gtr:name>UK HIV Vaccine Consortium (UKHVC)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E37A18E2-1E33-4ACE-BCFA-7DAD0DAF1261"><gtr:id>E37A18E2-1E33-4ACE-BCFA-7DAD0DAF1261</gtr:id><gtr:name>University of Regensburg</gtr:name><gtr:address><gtr:line1>University of Regensburg</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Germany</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/1C4A24DC-2FF4-47B7-B5FA-46BFF24DF5AB"><gtr:id>1C4A24DC-2FF4-47B7-B5FA-46BFF24DF5AB</gtr:id><gtr:name>National Institute for Medical Research</gtr:name><gtr:address><gtr:line1>Ocean Road</gtr:line1><gtr:line2>PO Box 9653</gtr:line2><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C754D612-4D8B-42CB-922C-07E7F5BE4B49"><gtr:id>C754D612-4D8B-42CB-922C-07E7F5BE4B49</gtr:id><gtr:name>Washington University in St. Louis</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C7FBE408-C743-4AAC-9BC6-65E14BC8D2FD"><gtr:id>C7FBE408-C743-4AAC-9BC6-65E14BC8D2FD</gtr:id><gtr:name>Karolinska Institute</gtr:name><gtr:address><gtr:line1>Administration</gtr:line1><gtr:line4>Stockholm</gtr:line4><gtr:postCode>SE-171 77</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Sweden</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F325BF32-08AE-4621-8057-E5D6613B7308"><gtr:id>F325BF32-08AE-4621-8057-E5D6613B7308</gtr:id><gtr:name>St George's University of London</gtr:name><gtr:address><gtr:line1>Cranmer Terrace</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>SW17 0RE</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5A8AC1E5-EA82-42CC-9E91-F0294FBF578B"><gtr:id>5A8AC1E5-EA82-42CC-9E91-F0294FBF578B</gtr:id><gtr:name>Robert Koch Institute</gtr:name><gtr:address><gtr:line1>Robert Koch Institut</gtr:line1><gtr:line2>Nordufer 20</gtr:line2><gtr:line4>D-13353 Berlin-Wedding</gtr:line4><gtr:region>Outside UK</gtr:region><gtr:country>Germany</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/99A20F70-F6B7-43DE-94E4-7004FAE6291E"><gtr:id>99A20F70-F6B7-43DE-94E4-7004FAE6291E</gtr:id><gtr:name>Ludwig Maximilians University Munich</gtr:name><gtr:address><gtr:line1>Geschwister-Scholl-Platz 1</gtr:line1><gtr:postCode>D-80539</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/FC75162A-C4F8-497E-AD42-5EEF4C35E48A"><gtr:id>FC75162A-C4F8-497E-AD42-5EEF4C35E48A</gtr:id><gtr:name>Infectious Disease Research Institute (IDRI)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5C1114A7-CE62-4DEC-BB95-695D6E2666CF"><gtr:id>5C1114A7-CE62-4DEC-BB95-695D6E2666CF</gtr:id><gtr:name>University of Verona</gtr:name><gtr:address><gtr:line1>strada le Grazie 15</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/8319F78A-DCBD-49F6-BE00-78E1CD75CDA9"><gtr:id>8319F78A-DCBD-49F6-BE00-78E1CD75CDA9</gtr:id><gtr:name>University of York</gtr:name><gtr:address><gtr:line1>Heslington</gtr:line1><gtr:line4>York</gtr:line4><gtr:line5>North Yorkshire</gtr:line5><gtr:postCode>YO10 5DD</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/49C44558-A75A-448F-9BF7-3F947FA67EB7"><gtr:id>49C44558-A75A-448F-9BF7-3F947FA67EB7</gtr:id><gtr:name>Technical University of Munich</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/67B34D05-3A52-4A09-8FF9-F2398D60E246"><gtr:id>67B34D05-3A52-4A09-8FF9-F2398D60E246</gtr:id><gtr:name>University of Surrey</gtr:name><gtr:address><gtr:line1>Registry</gtr:line1><gtr:line2>Stag Hill</gtr:line2><gtr:line4>Guildford</gtr:line4><gtr:line5>Surrey</gtr:line5><gtr:postCode>GU2 7XH</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/39147180-4991-4D6E-A137-E473AB40A04E"><gtr:id>39147180-4991-4D6E-A137-E473AB40A04E</gtr:id><gtr:name>International AIDS Vaccine Initiative (IAVI)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/7BC6FCF2-358C-45C5-A5A7-E859DD754711"><gtr:id>7BC6FCF2-358C-45C5-A5A7-E859DD754711</gtr:id><gtr:name>Lund University</gtr:name><gtr:address><gtr:line1>Box 117</gtr:line1><gtr:line2>S-221 00</gtr:line2><gtr:line4>Lund</gtr:line4><gtr:postCode>S-221 00</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Sweden</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/51CEB9A4-EEF4-4BC5-9845-AEA1B45A3AF8"><gtr:id>51CEB9A4-EEF4-4BC5-9845-AEA1B45A3AF8</gtr:id><gtr:name>French National Agency for Research on AIDS and Viral Hepatitis (ANRS)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/680A2524-B8AD-4E19-ACD2-3EECFCC5DAF1"><gtr:id>680A2524-B8AD-4E19-ACD2-3EECFCC5DAF1</gtr:id><gtr:name>Hull York Medical School</gtr:name><gtr:address><gtr:line1>John Hughlings Jackson Building</gtr:line1><gtr:postCode>YO10 5DD</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/36FCE8DD-97CB-47E6-A1E8-AE17410DD826"><gtr:id>36FCE8DD-97CB-47E6-A1E8-AE17410DD826</gtr:id><gtr:name>Government of Sweden</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2E8E7A84-3BC7-4739-986D-C05FC31789B8"><gtr:id>2E8E7A84-3BC7-4739-986D-C05FC31789B8</gtr:id><gtr:name>Charit? - University of Medicine Berlin</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C7B2F79C-C794-4597-898F-93292A2B77A3"><gtr:id>C7B2F79C-C794-4597-898F-93292A2B77A3</gtr:id><gtr:name>Fit Biotech Oy</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/63E44D26-67E6-4BB1-B63E-E2730AE68EB0"><gtr:id>63E44D26-67E6-4BB1-B63E-E2730AE68EB0</gtr:id><gtr:name>Braunschweig University of Technology</gtr:name><gtr:address><gtr:line1>Mendelssohnstr</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Germany</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/7E3C0045-B615-48B0-B761-74896FEED7ED"><gtr:id>7E3C0045-B615-48B0-B761-74896FEED7ED</gtr:id><gtr:firstName>Sheena</gtr:firstName><gtr:surname>McCormack</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_U122861400"><gtr:id>63EA45D8-A27A-43DB-855C-68DE5A049787</gtr:id><gtr:title>Prevention Programme - Vaccines (Eurovac)</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_U122861400</gtr:grantReference><gtr:abstractText>This large project brings together several experts in Europe in the HIV vaccine field. The efforts are concentrated on identifying candidate vaccines based on the C sub-type which circulates in Africa and China, and manufacturing them to high standards. They will then be tested for safety in clinical trials in healthy volunteers at low risk of HIV infection. Volunteers will be recruited from two centres: St Marys Hospital, London, UK and Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland, for the third trial extra centres have been added, Universitats Klinikum, Regensburg, Germany and six sites in France (co-ordinated by ANRS) The immune responses will be measured by testing (in the laboratory) the reactions of blood cells collected from volunteers. It is hoped that the candidate products will be safe and will evoke immune responses sufficiently encouraging to proceed to larger clinical trials. This third trial has completed recruitment and is now in followup.||A second part of the assessment of the candidates will be to monitor the immune responses to each product.</gtr:abstractText><gtr:technicalSummary>The aim of this programme was the development and early assessment of several novel HIV vaccine constructs. It is hoped that at least one immunogen will elicit a sufficiently broad and durable immune response to justify proceeding to a larger safety (Phase II) trial. The principal scientific objectives were: 1) to manufacture to Good Manufacturing Practice (GMP) standards 3 different constructs based on recombinant vaccinia vectors: MVA and NYVAC each containing a HIV clade B insert, and a NYVAC with a HIV clade C insert. DONE 2) to manufacture to GMP a DNA construct with a clade C insert. DONE 3) to manufacture to GMP a Semliki Forest Virus (SFV) vector with a clade C insert. FAILED DUE TO SCALE-UP DIFFICULTIES. 4) to manufacture to GMP a recombinant protein based on clade C envelope. DONE. 5) to assess the safety of these products in a series of clinical trials. EV01;NYVAC, EVO2; DNA/NYVAC vs NYVAC ALONE, EV03/ANRSvac20: 3DNA/1NYVAC vs 2DNA/2NYVAC 6) to compare the immunogenicity of the two vaccinia vectors in terms of ELISPOT responses to pools of gag peptides. FAILED DUE TO TIME CONSTRAINTS OF THE GRANT. 7) to compare the cellular immunogenicity of the clade C constructs (NYVAC, DNA, SFV). DNA NYVAC COMPARED TO NYVAC ALONE IN EV02. 8) to explore the cellular immunogenicity of combination regimens with these constructs SEE 7) ABOVE. 9) to explore the humoral immunogenicity of these constructs in regimens containing a recombinant protein boost. FAILED DUE TO TIME CONSTRAINTS OF THE GRANT. 10) to conduct parallel challenge experiments in animal models. DONE. The plan of the investigation The initial work will focus on producing the constructs to GMP. Once products become available they will undergo the necessary pre-clinical tests to underscore sterility, stability and lack of contaminant material as well as the repeated dose toxicity experiments required to support a Phase I clinical trial. The trials will be conducted in two clinical centres: St Marys Hospital, London UK and Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland. CTU will coordinate the development of the protocol, case record forms, database, monitoring and oversight (Trial Steering Committee and Data and Safety Monitoring Committee meetings).For Eurovac III (phaseI/II) an additional clinical centre was added: Universitats Klinikum, Regensburg, Germany plus under ANRS co-ordination 6 sites in France. The ELISPOT and intracellular cytokine assays will be conducted in Lausanne. Parallel challenge studies will be conducted in Holland.</gtr:technicalSummary><gtr:fund><gtr:end>2012-11-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2000-01-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>1265541</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs><gtr:artisticAndCreativeProductOutput><gtr:description>This was a documentary created by students and built around the personal experience of a close friend of theirs who had recently been diagnosed with HIV and who was considering participation in a research study.</gtr:description><gtr:id>99FC5D93-EEDF-47F9-BE37-537700909D37</gtr:id><gtr:impact>The film was well received at the graduation ceremony.</gtr:impact><gtr:outcomeId>545a62b8127631.50981537</gtr:outcomeId><gtr:title>Filming for Goldsmith's University BA Media student graduation documentary, 13th Jan. 2014</gtr:title><gtr:type>Film/Video/Animation</gtr:type><gtr:yearFirstProvided>2014</gtr:yearFirstProvided></gtr:artisticAndCreativeProductOutput></gtr:artisticAndCreativeProductOutputs><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Imperial College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>MucoVac 2</gtr:description><gtr:id>1C13CC9B-46F0-4EB4-A8FF-6331A44A91A4</gtr:id><gtr:impact>Trial protocol, CRF and database. 
Clinical study report.
Paper in presentation.</gtr:impact><gtr:outcomeId>kJqZu4bRLi7-4</gtr:outcomeId><gtr:partnerContribution>Provision of Clinical and laboratory facilities/staff for clincial trial. Responsibility for drafting reports and manuscripts. Trial sponsorship (SGUL) Coordination of drafting of trial protocol. Logistical and administrative support. Provision of product and collation of investigator brochure. Collation of submission to MHRA. Immunological analyses (Imperial).</gtr:partnerContribution><gtr:piContribution>Design of clinical trial, CRF, database and supporting documentation. Significant intellectual input into the drafting of the protocol. Co-ordination of networking between UKHVC (product), Helpmakehistory (volunteers). Responsibility for design of monitoring plan, monitoring of trial and preparation of relevant reports. Development of analysis plan and conducting analyses. Co-ordination of final report. Co-ordination of trial management.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Institute of Tropical Medicine Antwerp</gtr:collaboratingOrganisation><gtr:country>Belgium, Kingdom of</gtr:country><gtr:description>Europrise</gtr:description><gtr:id>2F763C2E-7AED-4093-BAA7-3B52F33C3C6A</gtr:id><gtr:impact>Publications in peer reviewed journals, collation (and publication) of webbased toolkit to support product development from bench to bedside, facilitation of networking across other projects, dissemination, statistical support.</gtr:impact><gtr:outcomeId>KBMd6icniRs-2</gtr:outcomeId><gtr:partnerContribution>Co-ordination of project, collation of reports, organisation of annual network meetings, facilitation of networking, organisation of training/workshops.</gtr:partnerContribution><gtr:piContribution>Co-ordination and administration of workpackage dedicated to translational clinical activities. Contribution to Dissemination and Advocacy workpage also.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Imperial College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>DNAVAC</gtr:description><gtr:id>94E31893-5D8C-46FE-ACC9-BAC439B736E7</gtr:id><gtr:impact>Protocol and regulatory submission.</gtr:impact><gtr:outcomeId>5462475338cbe7.72807170-1</gtr:outcomeId><gtr:partnerContribution>Product and immunological scientific rationale.</gtr:partnerContribution><gtr:piContribution>I contributed intellectually to the grant application by informing the clinical trial design, in particular the decision making process for going from the first stage of the investigation to the second.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>IrsiCaixa Institute for AIDS Research</gtr:collaboratingOrganisation><gtr:country>Spain, Kingdom of</gtr:country><gtr:description>CutHivac</gtr:description><gtr:id>F96A9C49-7C23-426F-8C2B-7AC998088015</gtr:id><gtr:impact>CutHivac001 a Phase I trial exploring the use of a novel mode of (prophylactic) vaccination in healthy volunteers fully enrolled (30 participants) in 2014, complete in 2015 and reported at two conferences: BHIVA 2016 and R4P 2016. Manuscript ready for submission.
CUHTHIVTHER a Phase II HIV therapeutic vaccine trial exploring different routes for delivering a DNA vaccine including transcutaneous and intramuscular with electroporation. 
Fully enrolled (30 participants) and completed in 2016. Clinical Study Report submitted to Sponsor, immunology complete and manuscript in draft.
CutHivac002 trials a Phase I prophylactic HIV vaccine trial exploring combination regimens with electroporation is underway and expected to complete in 2017.</gtr:impact><gtr:outcomeId>Lj9jG3qYyqz-5</gtr:outcomeId><gtr:partnerContribution>Co-ordination of the network activities via regular TC and annual investigator meetings. Collation of interim and annual reports. Integration of workpackages.</gtr:partnerContribution><gtr:piContribution>Responsibility for design of trial, analysis plan, drafting of protocol, harmonisation of data generated from other trials within network.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Institute for Medical Research, Tanzania</gtr:collaboratingOrganisation><gtr:country>Tanzania, United Republic of</gtr:country><gtr:description>TamoVac II</gtr:description><gtr:id>5C928CE6-1F37-4B0F-A701-D082FD5940C6</gtr:id><gtr:impact>Protocol, CRF, data management documentation including analysis plan, database validation and all that is required for a robust data management system.
Analysis workshop at MRC resulted in final analysis plan for TM 01 and design of TaMoVac II.
TaMoVac II completed; Clinical Study Report and manuscript in draft.</gtr:impact><gtr:outcomeId>qLPWvWDq3m7-4</gtr:outcomeId><gtr:partnerContribution>Provision of DNA and MVA. Sponsorship. Data management and statistical analysis. Building vaccine trial capacity in Tanzania and Mozambique by continued support and training to laboratory personnel to explore the responses to DNA priming and MVA boosting strategies. Co-ordination of the grant and organisation of annual investigator meetings.</gtr:partnerContribution><gtr:piContribution>Intellectual input into design of epidemiological studies preceding the trial, design of the trial, data management, analysis plan, CRF, drafting of protocol. Responsibility for coordination of monthly oversight, review of safety, overseeing the monitoring of clinical sites. Participation in annual investigator meetings.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of York</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Europrise</gtr:description><gtr:id>8883340C-CC04-4C6A-920F-AEE2BE7AB791</gtr:id><gtr:impact>Publications in peer reviewed journals, collation (and publication) of webbased toolkit to support product development from bench to bedside, facilitation of networking across other projects, dissemination, statistical support.</gtr:impact><gtr:outcomeId>KBMd6icniRs-10</gtr:outcomeId><gtr:partnerContribution>Co-ordination of project, collation of reports, organisation of annual network meetings, facilitation of networking, organisation of training/workshops.</gtr:partnerContribution><gtr:piContribution>Co-ordination and administration of workpackage dedicated to translational clinical activities. Contribution to Dissemination and Advocacy workpage also.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Institute for Biological Standards and Control (NIBSC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Europrise</gtr:description><gtr:id>2FB120A0-6FE7-4344-B040-AC6816405DD6</gtr:id><gtr:impact>Publications in peer reviewed journals, collation (and publication) of webbased toolkit to support product development from bench to bedside, facilitation of networking across other projects, dissemination, statistical support.</gtr:impact><gtr:outcomeId>KBMd6icniRs-8</gtr:outcomeId><gtr:partnerContribution>Co-ordination of project, collation of reports, organisation of annual network meetings, facilitation of networking, organisation of training/workshops.</gtr:partnerContribution><gtr:piContribution>Co-ordination and administration of workpackage dedicated to translational clinical activities. Contribution to Dissemination and Advocacy workpage also.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Lund University</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:description>Europrise</gtr:description><gtr:id>CE4CB7D2-7CDD-4DA5-8DB6-02646019231F</gtr:id><gtr:impact>Publications in peer reviewed journals, collation (and publication) of webbased toolkit to support product development from bench to bedside, facilitation of networking across other projects, dissemination, statistical support.</gtr:impact><gtr:outcomeId>KBMd6icniRs-11</gtr:outcomeId><gtr:partnerContribution>Co-ordination of project, collation of reports, organisation of annual network meetings, facilitation of networking, organisation of training/workshops.</gtr:partnerContribution><gtr:piContribution>Co-ordination and administration of workpackage dedicated to translational clinical activities. Contribution to Dissemination and Advocacy workpage also.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Sanofi Pasteur MSD</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>EV02</gtr:description><gtr:id>3B2D68E1-479F-4F79-BD06-5B5C75872F8E</gtr:id><gtr:impact>Final study report. Multiple publications in peer reviewed journals. 
Clear demonstration of the benefit of DNA priming.</gtr:impact><gtr:outcomeId>RwmUf5danK6-1</gtr:outcomeId><gtr:partnerContribution>Provision of DNA (University of Regensberg), NYVAC (Sanofi), Sponsorship (EuroVacc Foundation), immunological analyses (CHUV).
Input into drafting of protocol.</gtr:partnerContribution><gtr:piContribution>Design, data management and statistical analysis of this two centre Phase I HIV vaccine trial.
Co-ordination of trial management and responsibility for cross site monitoring.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Karolinska Institute</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:description>Europrise</gtr:description><gtr:id>06B23647-D190-4AAE-8A1E-2FC4B974F622</gtr:id><gtr:impact>Publications in peer reviewed journals, collation (and publication) of webbased toolkit to support product development from bench to bedside, facilitation of networking across other projects, dissemination, statistical support.</gtr:impact><gtr:outcomeId>KBMd6icniRs-3</gtr:outcomeId><gtr:partnerContribution>Co-ordination of project, collation of reports, organisation of annual network meetings, facilitation of networking, organisation of training/workshops.</gtr:partnerContribution><gtr:piContribution>Co-ordination and administration of workpackage dedicated to translational clinical activities. Contribution to Dissemination and Advocacy workpage also.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>St George's University of London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Division of Clinical Sciences</gtr:department><gtr:description>Europrise</gtr:description><gtr:id>CCC28D1E-E650-4C88-BD00-3FE0EF8CCA3A</gtr:id><gtr:impact>Publications in peer reviewed journals, collation (and publication) of webbased toolkit to support product development from bench to bedside, facilitation of networking across other projects, dissemination, statistical support.</gtr:impact><gtr:outcomeId>KBMd6icniRs-1</gtr:outcomeId><gtr:partnerContribution>Co-ordination of project, collation of reports, organisation of annual network meetings, facilitation of networking, organisation of training/workshops.</gtr:partnerContribution><gtr:piContribution>Co-ordination and administration of workpackage dedicated to translational clinical activities. Contribution to Dissemination and Advocacy workpage also.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Washington</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>IMPACTA Peru Clinical Trials Unit</gtr:department><gtr:description>CutHivac</gtr:description><gtr:id>3F6FEDC5-9063-4930-B8BB-48396E7D420E</gtr:id><gtr:impact>CutHivac001 a Phase I trial exploring the use of a novel mode of (prophylactic) vaccination in healthy volunteers fully enrolled (30 participants) in 2014, complete in 2015 and reported at two conferences: BHIVA 2016 and R4P 2016. Manuscript ready for submission.
CUHTHIVTHER a Phase II HIV therapeutic vaccine trial exploring different routes for delivering a DNA vaccine including transcutaneous and intramuscular with electroporation. 
Fully enrolled (30 participants) and completed in 2016. Clinical Study Report submitted to Sponsor, immunology complete and manuscript in draft.
CutHivac002 trials a Phase I prophylactic HIV vaccine trial exploring combination regimens with electroporation is underway and expected to complete in 2017.</gtr:impact><gtr:outcomeId>Lj9jG3qYyqz-7</gtr:outcomeId><gtr:partnerContribution>Co-ordination of the network activities via regular TC and annual investigator meetings. Collation of interim and annual reports. Integration of workpackages.</gtr:partnerContribution><gtr:piContribution>Responsibility for design of trial, analysis plan, drafting of protocol, harmonisation of data generated from other trials within network.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Imperial College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>EV03</gtr:description><gtr:id>C1E7E9F3-E2CB-40A4-A7C1-7C5CE95C2D86</gtr:id><gtr:impact>Presentation of results at international meetings (CROI, AIDS vaccine 2010, 2013). 
Final study report. 
Paper in preparation.</gtr:impact><gtr:outcomeId>caH6TbQ2odq-7</gtr:outcomeId><gtr:partnerContribution>Eurovacc co-sponsored this Phase IIa trial with ANRS.
IMPD (Eurovacc). Provision of NYVAC C (Eurovacc). Provision of DNA (University of Regensburg). Input into analysis (INSERM). Immunological assays (CHUV &amp;amp; ANRS).</gtr:partnerContribution><gtr:piContribution>Significant intellectual input into design of protocol, CRF, database, supporting documentation, analysis plan and monitoring plan. Co-ordination of trial management and responsibility for cross site monitoring. Analysis of data.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>European AIDS Treatment Group (EATG)</gtr:collaboratingOrganisation><gtr:country>European Union (EU)</gtr:country><gtr:description>Europrise</gtr:description><gtr:id>6B599720-8E03-4D5E-9F9E-D3972B2D1954</gtr:id><gtr:impact>Publications in peer reviewed journals, collation (and publication) of webbased toolkit to support product development from bench to bedside, facilitation of networking across other projects, dissemination, statistical support.</gtr:impact><gtr:outcomeId>KBMd6icniRs-14</gtr:outcomeId><gtr:partnerContribution>Co-ordination of project, collation of reports, organisation of annual network meetings, facilitation of networking, organisation of training/workshops.</gtr:partnerContribution><gtr:piContribution>Co-ordination and administration of workpackage dedicated to translational clinical activities. Contribution to Dissemination and Advocacy workpage also.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Robert Koch-Institut RKI</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>Europrise</gtr:description><gtr:id>A96D427D-4E58-4205-9E25-FC1CF4ECB24E</gtr:id><gtr:impact>Publications in peer reviewed journals, collation (and publication) of webbased toolkit to support product development from bench to bedside, facilitation of networking across other projects, dissemination, statistical support.</gtr:impact><gtr:outcomeId>KBMd6icniRs-13</gtr:outcomeId><gtr:partnerContribution>Co-ordination of project, collation of reports, organisation of annual network meetings, facilitation of networking, organisation of training/workshops.</gtr:partnerContribution><gtr:piContribution>Co-ordination and administration of workpackage dedicated to translational clinical activities. Contribution to Dissemination and Advocacy workpage also.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>International AIDS Vaccine Initiative (IAVI)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Human Immunology Laboratory, ICL</gtr:department><gtr:description>UKHVC spoke 03 (MRC DCS scheme)</gtr:description><gtr:id>D0B8C1BE-0F04-49FA-B1C3-0D43F56C46BD</gtr:id><gtr:impact>Spoke 03 trial is fully recruited, completed and reported (see publications).</gtr:impact><gtr:outcomeId>JQh8Yjoazh2-4</gtr:outcomeId><gtr:partnerContribution>University of Surrey/Imperial College: recruitment and follow up of trial participants.
Trial management &amp;amp; analysis: Imperial College, with oversight/input from the MRC Clinical Trials Unit at UCL.</gtr:partnerContribution><gtr:piContribution>Oversight of clinical trial management and statistical analysis. Attendance at regular trial management group teleconferences.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Fit Biotech Oy</gtr:collaboratingOrganisation><gtr:country>Finland, Republic of</gtr:country><gtr:description>CutHivac</gtr:description><gtr:id>12CC54F8-2D24-480B-9F23-0E332B878980</gtr:id><gtr:impact>CutHivac001 a Phase I trial exploring the use of a novel mode of (prophylactic) vaccination in healthy volunteers fully enrolled (30 participants) in 2014, complete in 2015 and reported at two conferences: BHIVA 2016 and R4P 2016. Manuscript ready for submission.
CUHTHIVTHER a Phase II HIV therapeutic vaccine trial exploring different routes for delivering a DNA vaccine including transcutaneous and intramuscular with electroporation. 
Fully enrolled (30 participants) and completed in 2016. Clinical Study Report submitted to Sponsor, immunology complete and manuscript in draft.
CutHivac002 trials a Phase I prophylactic HIV vaccine trial exploring combination regimens with electroporation is underway and expected to complete in 2017.</gtr:impact><gtr:outcomeId>Lj9jG3qYyqz-3</gtr:outcomeId><gtr:partnerContribution>Co-ordination of the network activities via regular TC and annual investigator meetings. Collation of interim and annual reports. Integration of workpackages.</gtr:partnerContribution><gtr:piContribution>Responsibility for design of trial, analysis plan, drafting of protocol, harmonisation of data generated from other trials within network.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Siena</gtr:collaboratingOrganisation><gtr:country>Italy, Italian Republic</gtr:country><gtr:description>Europrise</gtr:description><gtr:id>6D53371E-0E21-4C43-B545-9F9DFEDC85A4</gtr:id><gtr:impact>Publications in peer reviewed journals, collation (and publication) of webbased toolkit to support product development from bench to bedside, facilitation of networking across other projects, dissemination, statistical support.</gtr:impact><gtr:outcomeId>KBMd6icniRs-6</gtr:outcomeId><gtr:partnerContribution>Co-ordination of project, collation of reports, organisation of annual network meetings, facilitation of networking, organisation of training/workshops.</gtr:partnerContribution><gtr:piContribution>Co-ordination and administration of workpackage dedicated to translational clinical activities. Contribution to Dissemination and Advocacy workpage also.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>GlaxoSmithKline (GSK)</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>Europrise</gtr:description><gtr:id>1F934AC4-FCB8-470F-8743-347DFAB7049D</gtr:id><gtr:impact>Publications in peer reviewed journals, collation (and publication) of webbased toolkit to support product development from bench to bedside, facilitation of networking across other projects, dissemination, statistical support.</gtr:impact><gtr:outcomeId>KBMd6icniRs-4</gtr:outcomeId><gtr:partnerContribution>Co-ordination of project, collation of reports, organisation of annual network meetings, facilitation of networking, organisation of training/workshops.</gtr:partnerContribution><gtr:piContribution>Co-ordination and administration of workpackage dedicated to translational clinical activities. Contribution to Dissemination and Advocacy workpage also.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Lausanne University Hospital  (CHUV)</gtr:collaboratingOrganisation><gtr:country>Switzerland, Swiss Confederation</gtr:country><gtr:description>EV02</gtr:description><gtr:id>429341CF-04CC-4B68-B49C-AE27F6F858E0</gtr:id><gtr:impact>Final study report. Multiple publications in peer reviewed journals. 
Clear demonstration of the benefit of DNA priming.</gtr:impact><gtr:outcomeId>RwmUf5danK6-4</gtr:outcomeId><gtr:partnerContribution>Provision of DNA (University of Regensberg), NYVAC (Sanofi), Sponsorship (EuroVacc Foundation), immunological analyses (CHUV).
Input into drafting of protocol.</gtr:partnerContribution><gtr:piContribution>Design, data management and statistical analysis of this two centre Phase I HIV vaccine trial.
Co-ordination of trial management and responsibility for cross site monitoring.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Braunschweig University of Technology</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:department>Helmholtz-Zentrum f?r Infektionsforschung</gtr:department><gtr:description>TRANSVAC</gtr:description><gtr:id>2E9410FF-B445-4290-A818-75E37BC36FB7</gtr:id><gtr:impact>Bioinformatice Analysis is ongoing and will lead to publication and strengthening of infrastructure and expertise within the consortium.</gtr:impact><gtr:outcomeId>aUhNHqNH37L-2</gtr:outcomeId><gtr:partnerContribution>Unversity of Munich supplied man power and also access to samples from vaccinated and chronically infected individuals for deep sequencing. The facility at Helmholtz supplied access to deep sequencing technology and expertise.</gtr:partnerContribution><gtr:piContribution>Sarah Joseph was a lead applicant on an application made to TRANSVAC for access to deep sequencing technology.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Imperial College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Faculty of Medicine</gtr:department><gtr:description>UK HIV Vaccine Consortium</gtr:description><gtr:id>0994C473-40BE-4B29-9A5C-37EDD01FC080</gtr:id><gtr:impact>GMP material for clinical trials manufactured and procured with due diligence on intellectual property.
Annual UK HIV vaccine scientist meeting to review progress and comment on proposals, including meeting in March 2015 to determine whether or not to proceed to efficacy testing of current products.
Several clinical trials that were being conducted in our networks were provided partial support that facilitated completion and full analyses including CUTHIVAC and TaMoVac trials.</gtr:impact><gtr:outcomeId>hVGxkdxs6Zn-1</gtr:outcomeId><gtr:partnerContribution>Intellectual contributions to the design of trials, oversight and provision of GMP and supporting documentation such as the Investigator Brochure, provision of clinical facilities and expert personnel to conduct Phase I HIV vaccine trials, central coordination of the administrative aspects of the award.</gtr:partnerContribution><gtr:piContribution>Design including sample size rationale, drafting complementary grant applications, protocols, CRFs, trial documentation including analysis plan and submissions to competent authority, designing the central database, extracting and analysing data, preparing reports including the final Clinical Study Report.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Surrey</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>UKHVC spoke 03 (MRC DCS scheme)</gtr:description><gtr:id>A0F39B4E-696F-49CE-A919-AC50F58534A1</gtr:id><gtr:impact>Spoke 03 trial is fully recruited, completed and reported (see publications).</gtr:impact><gtr:outcomeId>JQh8Yjoazh2-3</gtr:outcomeId><gtr:partnerContribution>University of Surrey/Imperial College: recruitment and follow up of trial participants.
Trial management &amp;amp; analysis: Imperial College, with oversight/input from the MRC Clinical Trials Unit at UCL.</gtr:partnerContribution><gtr:piContribution>Oversight of clinical trial management and statistical analysis. Attendance at regular trial management group teleconferences.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>UK HIV Vaccine Consortium</gtr:description><gtr:id>9FB80D36-22FD-42B5-8F04-FBBCEFA9CCF8</gtr:id><gtr:impact>GMP material for clinical trials manufactured and procured with due diligence on intellectual property.
Annual UK HIV vaccine scientist meeting to review progress and comment on proposals, including meeting in March 2015 to determine whether or not to proceed to efficacy testing of current products.
Several clinical trials that were being conducted in our networks were provided partial support that facilitated completion and full analyses including CUTHIVAC and TaMoVac trials.</gtr:impact><gtr:outcomeId>hVGxkdxs6Zn-2</gtr:outcomeId><gtr:partnerContribution>Intellectual contributions to the design of trials, oversight and provision of GMP and supporting documentation such as the Investigator Brochure, provision of clinical facilities and expert personnel to conduct Phase I HIV vaccine trials, central coordination of the administrative aspects of the award.</gtr:partnerContribution><gtr:piContribution>Design including sample size rationale, drafting complementary grant applications, protocols, CRFs, trial documentation including analysis plan and submissions to competent authority, designing the central database, extracting and analysing data, preparing reports including the final Clinical Study Report.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Regensburg</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>EV03</gtr:description><gtr:id>EB505EDE-4ADF-4DAD-9A83-7DDBE0A69816</gtr:id><gtr:impact>Presentation of results at international meetings (CROI, AIDS vaccine 2010, 2013). 
Final study report. 
Paper in preparation.</gtr:impact><gtr:outcomeId>caH6TbQ2odq-5</gtr:outcomeId><gtr:partnerContribution>Eurovacc co-sponsored this Phase IIa trial with ANRS.
IMPD (Eurovacc). Provision of NYVAC C (Eurovacc). Provision of DNA (University of Regensburg). Input into analysis (INSERM). Immunological assays (CHUV &amp;amp; ANRS).</gtr:partnerContribution><gtr:piContribution>Significant intellectual input into design of protocol, CRF, database, supporting documentation, analysis plan and monitoring plan. Co-ordination of trial management and responsibility for cross site monitoring. Analysis of data.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Regensburg</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>EV02</gtr:description><gtr:id>D07E984E-B2C5-4F9D-9A1A-AD87BB83AB70</gtr:id><gtr:impact>Final study report. Multiple publications in peer reviewed journals. 
Clear demonstration of the benefit of DNA priming.</gtr:impact><gtr:outcomeId>RwmUf5danK6-3</gtr:outcomeId><gtr:partnerContribution>Provision of DNA (University of Regensberg), NYVAC (Sanofi), Sponsorship (EuroVacc Foundation), immunological analyses (CHUV).
Input into drafting of protocol.</gtr:partnerContribution><gtr:piContribution>Design, data management and statistical analysis of this two centre Phase I HIV vaccine trial.
Co-ordination of trial management and responsibility for cross site monitoring.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Imperial College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>UKHVC spoke 03 (MRC DCS scheme)</gtr:description><gtr:id>4F5D01D9-6064-4F96-A67A-7B768211C33D</gtr:id><gtr:impact>Spoke 03 trial is fully recruited, completed and reported (see publications).</gtr:impact><gtr:outcomeId>JQh8Yjoazh2-1</gtr:outcomeId><gtr:partnerContribution>University of Surrey/Imperial College: recruitment and follow up of trial participants.
Trial management &amp;amp; analysis: Imperial College, with oversight/input from the MRC Clinical Trials Unit at UCL.</gtr:partnerContribution><gtr:piContribution>Oversight of clinical trial management and statistical analysis. Attendance at regular trial management group teleconferences.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>St George's University of London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Cellular and Molecular Medicine</gtr:department><gtr:description>MucoVac 2</gtr:description><gtr:id>01262EDD-B9EE-461A-A94C-A843BA529AFF</gtr:id><gtr:impact>Trial protocol, CRF and database. 
Clinical study report.
Paper in presentation.</gtr:impact><gtr:outcomeId>kJqZu4bRLi7-1</gtr:outcomeId><gtr:partnerContribution>Provision of Clinical and laboratory facilities/staff for clincial trial. Responsibility for drafting reports and manuscripts. Trial sponsorship (SGUL) Coordination of drafting of trial protocol. Logistical and administrative support. Provision of product and collation of investigator brochure. Collation of submission to MHRA. Immunological analyses (Imperial).</gtr:partnerContribution><gtr:piContribution>Design of clinical trial, CRF, database and supporting documentation. Significant intellectual input into the drafting of the protocol. Co-ordination of networking between UKHVC (product), Helpmakehistory (volunteers). Responsibility for design of monitoring plan, monitoring of trial and preparation of relevant reports. Development of analysis plan and conducting analyses. Co-ordination of final report. Co-ordination of trial management.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Imperial College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>CutHivac</gtr:description><gtr:id>C0E7F4C9-7EEE-4FD9-A5EA-6C10C9BDB7D1</gtr:id><gtr:impact>CutHivac001 a Phase I trial exploring the use of a novel mode of (prophylactic) vaccination in healthy volunteers fully enrolled (30 participants) in 2014, complete in 2015 and reported at two conferences: BHIVA 2016 and R4P 2016. Manuscript ready for submission.
CUHTHIVTHER a Phase II HIV therapeutic vaccine trial exploring different routes for delivering a DNA vaccine including transcutaneous and intramuscular with electroporation. 
Fully enrolled (30 participants) and completed in 2016. Clinical Study Report submitted to Sponsor, immunology complete and manuscript in draft.
CutHivac002 trials a Phase I prophylactic HIV vaccine trial exploring combination regimens with electroporation is underway and expected to complete in 2017.</gtr:impact><gtr:outcomeId>Lj9jG3qYyqz-2</gtr:outcomeId><gtr:partnerContribution>Co-ordination of the network activities via regular TC and annual investigator meetings. Collation of interim and annual reports. Integration of workpackages.</gtr:partnerContribution><gtr:piContribution>Responsibility for design of trial, analysis plan, drafting of protocol, harmonisation of data generated from other trials within network.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Institute of Health and Medical Research (INSERM)</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:description>EV03</gtr:description><gtr:id>BDD64B9F-AD65-46E9-859A-20B0AA8563C7</gtr:id><gtr:impact>Presentation of results at international meetings (CROI, AIDS vaccine 2010, 2013). 
Final study report. 
Paper in preparation.</gtr:impact><gtr:outcomeId>caH6TbQ2odq-4</gtr:outcomeId><gtr:partnerContribution>Eurovacc co-sponsored this Phase IIa trial with ANRS.
IMPD (Eurovacc). Provision of NYVAC C (Eurovacc). Provision of DNA (University of Regensburg). Input into analysis (INSERM). Immunological assays (CHUV &amp;amp; ANRS).</gtr:partnerContribution><gtr:piContribution>Significant intellectual input into design of protocol, CRF, database, supporting documentation, analysis plan and monitoring plan. Co-ordination of trial management and responsibility for cross site monitoring. Analysis of data.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>UK HIV Vaccine Consortium (UKHVC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Dr. Sarah Joseph collaboration with Chriss Geldmacher: Epitope mapping project</gtr:description><gtr:id>0A494876-AD31-4142-8223-55C6EE83B8DA</gtr:id><gtr:impact>Preliminary results presented data to UKHVC - analysis ongoing</gtr:impact><gtr:outcomeId>5464a68646b457.63631989-2</gtr:outcomeId><gtr:partnerContribution>Expert in the technology needed for the project. Major financial contribution to the project.</gtr:partnerContribution><gtr:piContribution>Jointing drafted the application and contributed to the design of the study.
UKHVC supplied samples for cross comparison studies between other trials.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Novartis</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>Europrise</gtr:description><gtr:id>D7AAE962-63FC-4D2B-95FB-DD7A3041F90B</gtr:id><gtr:impact>Publications in peer reviewed journals, collation (and publication) of webbased toolkit to support product development from bench to bedside, facilitation of networking across other projects, dissemination, statistical support.</gtr:impact><gtr:outcomeId>KBMd6icniRs-5</gtr:outcomeId><gtr:partnerContribution>Co-ordination of project, collation of reports, organisation of annual network meetings, facilitation of networking, organisation of training/workshops.</gtr:partnerContribution><gtr:piContribution>Co-ordination and administration of workpackage dedicated to translational clinical activities. Contribution to Dissemination and Advocacy workpage also.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Ludwig Maximilian University of Munich (LMU Munich)</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:department>Institute of Immunology</gtr:department><gtr:description>TRANSVAC</gtr:description><gtr:id>98D5B136-EAFD-4A3B-BACB-A53AEE6F951E</gtr:id><gtr:impact>Bioinformatice Analysis is ongoing and will lead to publication and strengthening of infrastructure and expertise within the consortium.</gtr:impact><gtr:outcomeId>aUhNHqNH37L-1</gtr:outcomeId><gtr:partnerContribution>Unversity of Munich supplied man power and also access to samples from vaccinated and chronically infected individuals for deep sequencing. The facility at Helmholtz supplied access to deep sequencing technology and expertise.</gtr:partnerContribution><gtr:piContribution>Sarah Joseph was a lead applicant on an application made to TRANSVAC for access to deep sequencing technology.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Institute of Health and Medical Research (INSERM)</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:department>INSERM U543 (Cellular and Tissue Immunology Laboratory)</gtr:department><gtr:description>CutHivac</gtr:description><gtr:id>F8275499-6E8A-4AD1-A470-3DDB3E7FE3B3</gtr:id><gtr:impact>CutHivac001 a Phase I trial exploring the use of a novel mode of (prophylactic) vaccination in healthy volunteers fully enrolled (30 participants) in 2014, complete in 2015 and reported at two conferences: BHIVA 2016 and R4P 2016. Manuscript ready for submission.
CUHTHIVTHER a Phase II HIV therapeutic vaccine trial exploring different routes for delivering a DNA vaccine including transcutaneous and intramuscular with electroporation. 
Fully enrolled (30 participants) and completed in 2016. Clinical Study Report submitted to Sponsor, immunology complete and manuscript in draft.
CutHivac002 trials a Phase I prophylactic HIV vaccine trial exploring combination regimens with electroporation is underway and expected to complete in 2017.</gtr:impact><gtr:outcomeId>Lj9jG3qYyqz-1</gtr:outcomeId><gtr:partnerContribution>Co-ordination of the network activities via regular TC and annual investigator meetings. Collation of interim and annual reports. Integration of workpackages.</gtr:partnerContribution><gtr:piContribution>Responsibility for design of trial, analysis plan, drafting of protocol, harmonisation of data generated from other trials within network.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Charit? - University of Medicine Berlin</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>CutHivac</gtr:description><gtr:id>63398E39-6224-4A2C-9BA8-F5EC165B3C7C</gtr:id><gtr:impact>CutHivac001 a Phase I trial exploring the use of a novel mode of (prophylactic) vaccination in healthy volunteers fully enrolled (30 participants) in 2014, complete in 2015 and reported at two conferences: BHIVA 2016 and R4P 2016. Manuscript ready for submission.
CUHTHIVTHER a Phase II HIV therapeutic vaccine trial exploring different routes for delivering a DNA vaccine including transcutaneous and intramuscular with electroporation. 
Fully enrolled (30 participants) and completed in 2016. Clinical Study Report submitted to Sponsor, immunology complete and manuscript in draft.
CutHivac002 trials a Phase I prophylactic HIV vaccine trial exploring combination regimens with electroporation is underway and expected to complete in 2017.</gtr:impact><gtr:outcomeId>Lj9jG3qYyqz-4</gtr:outcomeId><gtr:partnerContribution>Co-ordination of the network activities via regular TC and annual investigator meetings. Collation of interim and annual reports. Integration of workpackages.</gtr:partnerContribution><gtr:piContribution>Responsibility for design of trial, analysis plan, drafting of protocol, harmonisation of data generated from other trials within network.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Imperial College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>TamoVac II</gtr:description><gtr:id>A5957C69-C72C-414B-9FC2-AACBE3D9C283</gtr:id><gtr:impact>Protocol, CRF, data management documentation including analysis plan, database validation and all that is required for a robust data management system.
Analysis workshop at MRC resulted in final analysis plan for TM 01 and design of TaMoVac II.
TaMoVac II completed; Clinical Study Report and manuscript in draft.</gtr:impact><gtr:outcomeId>qLPWvWDq3m7-6</gtr:outcomeId><gtr:partnerContribution>Provision of DNA and MVA. Sponsorship. Data management and statistical analysis. Building vaccine trial capacity in Tanzania and Mozambique by continued support and training to laboratory personnel to explore the responses to DNA priming and MVA boosting strategies. Co-ordination of the grant and organisation of annual investigator meetings.</gtr:partnerContribution><gtr:piContribution>Intellectual input into design of epidemiological studies preceding the trial, design of the trial, data management, analysis plan, CRF, drafting of protocol. Responsibility for coordination of monthly oversight, review of safety, overseeing the monitoring of clinical sites. Participation in annual investigator meetings.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Eurovacc Foundation</gtr:collaboratingOrganisation><gtr:country>Switzerland, Swiss Confederation</gtr:country><gtr:description>EV02</gtr:description><gtr:id>37904E44-9A78-4AFA-A6DB-8906BABDBFF3</gtr:id><gtr:impact>Final study report. Multiple publications in peer reviewed journals. 
Clear demonstration of the benefit of DNA priming.</gtr:impact><gtr:outcomeId>RwmUf5danK6-2</gtr:outcomeId><gtr:partnerContribution>Provision of DNA (University of Regensberg), NYVAC (Sanofi), Sponsorship (EuroVacc Foundation), immunological analyses (CHUV).
Input into drafting of protocol.</gtr:partnerContribution><gtr:piContribution>Design, data management and statistical analysis of this two centre Phase I HIV vaccine trial.
Co-ordination of trial management and responsibility for cross site monitoring.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Muhimbili University of Health and Allied Sciences</gtr:collaboratingOrganisation><gtr:country>Tanzania, United Republic of</gtr:country><gtr:department>Department of Microbiology and Immunology</gtr:department><gtr:description>TamoVac II</gtr:description><gtr:id>6C91F4B7-03A8-463F-952D-94AEF27C0303</gtr:id><gtr:impact>Protocol, CRF, data management documentation including analysis plan, database validation and all that is required for a robust data management system.
Analysis workshop at MRC resulted in final analysis plan for TM 01 and design of TaMoVac II.
TaMoVac II completed; Clinical Study Report and manuscript in draft.</gtr:impact><gtr:outcomeId>qLPWvWDq3m7-1</gtr:outcomeId><gtr:partnerContribution>Provision of DNA and MVA. Sponsorship. Data management and statistical analysis. Building vaccine trial capacity in Tanzania and Mozambique by continued support and training to laboratory personnel to explore the responses to DNA priming and MVA boosting strategies. Co-ordination of the grant and organisation of annual investigator meetings.</gtr:partnerContribution><gtr:piContribution>Intellectual input into design of epidemiological studies preceding the trial, design of the trial, data management, analysis plan, CRF, drafting of protocol. Responsibility for coordination of monthly oversight, review of safety, overseeing the monitoring of clinical sites. Participation in annual investigator meetings.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Infectious Disease Research Institute (IDRI)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>UKHVC spoke 03 (MRC DCS scheme)</gtr:description><gtr:id>1785DEAF-8DBA-4332-AEC8-B3702F923112</gtr:id><gtr:impact>Spoke 03 trial is fully recruited, completed and reported (see publications).</gtr:impact><gtr:outcomeId>JQh8Yjoazh2-2</gtr:outcomeId><gtr:partnerContribution>University of Surrey/Imperial College: recruitment and follow up of trial participants.
Trial management &amp;amp; analysis: Imperial College, with oversight/input from the MRC Clinical Trials Unit at UCL.</gtr:partnerContribution><gtr:piContribution>Oversight of clinical trial management and statistical analysis. Attendance at regular trial management group teleconferences.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Eurovacc Foundation</gtr:collaboratingOrganisation><gtr:country>Switzerland, Swiss Confederation</gtr:country><gtr:description>EV03</gtr:description><gtr:id>A74C69F4-963A-431C-96CB-A47BF2E19349</gtr:id><gtr:impact>Presentation of results at international meetings (CROI, AIDS vaccine 2010, 2013). 
Final study report. 
Paper in preparation.</gtr:impact><gtr:outcomeId>caH6TbQ2odq-2</gtr:outcomeId><gtr:partnerContribution>Eurovacc co-sponsored this Phase IIa trial with ANRS.
IMPD (Eurovacc). Provision of NYVAC C (Eurovacc). Provision of DNA (University of Regensburg). Input into analysis (INSERM). Immunological assays (CHUV &amp;amp; ANRS).</gtr:partnerContribution><gtr:piContribution>Significant intellectual input into design of protocol, CRF, database, supporting documentation, analysis plan and monitoring plan. Co-ordination of trial management and responsibility for cross site monitoring. Analysis of data.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Institute for Medical Research, Tanzania</gtr:collaboratingOrganisation><gtr:country>Tanzania, United Republic of</gtr:country><gtr:department>NIMR Mbeya Research Centre (Formerly known as; Mbeya Medical Research Programme, MMPR)</gtr:department><gtr:description>TamoVac II</gtr:description><gtr:id>2E83724B-0FC7-42FD-8258-57BA927BB11D</gtr:id><gtr:impact>Protocol, CRF, data management documentation including analysis plan, database validation and all that is required for a robust data management system.
Analysis workshop at MRC resulted in final analysis plan for TM 01 and design of TaMoVac II.
TaMoVac II completed; Clinical Study Report and manuscript in draft.</gtr:impact><gtr:outcomeId>qLPWvWDq3m7-3</gtr:outcomeId><gtr:partnerContribution>Provision of DNA and MVA. Sponsorship. Data management and statistical analysis. Building vaccine trial capacity in Tanzania and Mozambique by continued support and training to laboratory personnel to explore the responses to DNA priming and MVA boosting strategies. Co-ordination of the grant and organisation of annual investigator meetings.</gtr:partnerContribution><gtr:piContribution>Intellectual input into design of epidemiological studies preceding the trial, design of the trial, data management, analysis plan, CRF, drafting of protocol. Responsibility for coordination of monthly oversight, review of safety, overseeing the monitoring of clinical sites. Participation in annual investigator meetings.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>French National Agency for Research on AIDS and Viral Hepatitis (ANRS)</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:description>EV03</gtr:description><gtr:id>CE172450-D188-4D3A-9578-5A205ED00242</gtr:id><gtr:impact>Presentation of results at international meetings (CROI, AIDS vaccine 2010, 2013). 
Final study report. 
Paper in preparation.</gtr:impact><gtr:outcomeId>caH6TbQ2odq-3</gtr:outcomeId><gtr:partnerContribution>Eurovacc co-sponsored this Phase IIa trial with ANRS.
IMPD (Eurovacc). Provision of NYVAC C (Eurovacc). Provision of DNA (University of Regensburg). Input into analysis (INSERM). Immunological assays (CHUV &amp;amp; ANRS).</gtr:partnerContribution><gtr:piContribution>Significant intellectual input into design of protocol, CRF, database, supporting documentation, analysis plan and monitoring plan. Co-ordination of trial management and responsibility for cross site monitoring. Analysis of data.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>ALTA</gtr:collaboratingOrganisation><gtr:country>Italy, Italian Republic</gtr:country><gtr:description>Europrise</gtr:description><gtr:id>0DA9C979-FA31-4C79-B732-5D9238EA2CEE</gtr:id><gtr:impact>Publications in peer reviewed journals, collation (and publication) of webbased toolkit to support product development from bench to bedside, facilitation of networking across other projects, dissemination, statistical support.</gtr:impact><gtr:outcomeId>KBMd6icniRs-7</gtr:outcomeId><gtr:partnerContribution>Co-ordination of project, collation of reports, organisation of annual network meetings, facilitation of networking, organisation of training/workshops.</gtr:partnerContribution><gtr:piContribution>Co-ordination and administration of workpackage dedicated to translational clinical activities. Contribution to Dissemination and Advocacy workpage also.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Institute of Health, Mozambique (Instituto Nacional de Sa?de)</gtr:collaboratingOrganisation><gtr:country>Mozambique, Republic of</gtr:country><gtr:description>TamoVac II</gtr:description><gtr:id>2E2B322D-EDD6-4262-AE83-9F3C7AFC4E96</gtr:id><gtr:impact>Protocol, CRF, data management documentation including analysis plan, database validation and all that is required for a robust data management system.
Analysis workshop at MRC resulted in final analysis plan for TM 01 and design of TaMoVac II.
TaMoVac II completed; Clinical Study Report and manuscript in draft.</gtr:impact><gtr:outcomeId>qLPWvWDq3m7-5</gtr:outcomeId><gtr:partnerContribution>Provision of DNA and MVA. Sponsorship. Data management and statistical analysis. Building vaccine trial capacity in Tanzania and Mozambique by continued support and training to laboratory personnel to explore the responses to DNA priming and MVA boosting strategies. Co-ordination of the grant and organisation of annual investigator meetings.</gtr:partnerContribution><gtr:piContribution>Intellectual input into design of epidemiological studies preceding the trial, design of the trial, data management, analysis plan, CRF, drafting of protocol. Responsibility for coordination of monthly oversight, review of safety, overseeing the monitoring of clinical sites. Participation in annual investigator meetings.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Hull York Medical School</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>MucoVac 2</gtr:description><gtr:id>FDF85F7E-D4C5-4987-9969-B174E17B6720</gtr:id><gtr:impact>Trial protocol, CRF and database. 
Clinical study report.
Paper in presentation.</gtr:impact><gtr:outcomeId>kJqZu4bRLi7-2</gtr:outcomeId><gtr:partnerContribution>Provision of Clinical and laboratory facilities/staff for clincial trial. Responsibility for drafting reports and manuscripts. Trial sponsorship (SGUL) Coordination of drafting of trial protocol. Logistical and administrative support. Provision of product and collation of investigator brochure. Collation of submission to MHRA. Immunological analyses (Imperial).</gtr:partnerContribution><gtr:piContribution>Design of clinical trial, CRF, database and supporting documentation. Significant intellectual input into the drafting of the protocol. Co-ordination of networking between UKHVC (product), Helpmakehistory (volunteers). Responsibility for design of monitoring plan, monitoring of trial and preparation of relevant reports. Development of analysis plan and conducting analyses. Co-ordination of final report. Co-ordination of trial management.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Technical University of Munich</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>TamoVac II</gtr:description><gtr:id>9088D8FA-F7B9-4CBD-9949-186ABDDEDC73</gtr:id><gtr:impact>Protocol, CRF, data management documentation including analysis plan, database validation and all that is required for a robust data management system.
Analysis workshop at MRC resulted in final analysis plan for TM 01 and design of TaMoVac II.
TaMoVac II completed; Clinical Study Report and manuscript in draft.</gtr:impact><gtr:outcomeId>qLPWvWDq3m7-7</gtr:outcomeId><gtr:partnerContribution>Provision of DNA and MVA. Sponsorship. Data management and statistical analysis. Building vaccine trial capacity in Tanzania and Mozambique by continued support and training to laboratory personnel to explore the responses to DNA priming and MVA boosting strategies. Co-ordination of the grant and organisation of annual investigator meetings.</gtr:partnerContribution><gtr:piContribution>Intellectual input into design of epidemiological studies preceding the trial, design of the trial, data management, analysis plan, CRF, drafting of protocol. Responsibility for coordination of monthly oversight, review of safety, overseeing the monitoring of clinical sites. Participation in annual investigator meetings.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Government of Sweden</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:department>Swedish Institute for Infectious Disease Control (Smittskyddsinstitutet SMI/SIIDC)</gtr:department><gtr:description>TamoVac II</gtr:description><gtr:id>EC0FBA37-D94A-4099-8FFB-3F659416DCC1</gtr:id><gtr:impact>Protocol, CRF, data management documentation including analysis plan, database validation and all that is required for a robust data management system.
Analysis workshop at MRC resulted in final analysis plan for TM 01 and design of TaMoVac II.
TaMoVac II completed; Clinical Study Report and manuscript in draft.</gtr:impact><gtr:outcomeId>qLPWvWDq3m7-2</gtr:outcomeId><gtr:partnerContribution>Provision of DNA and MVA. Sponsorship. Data management and statistical analysis. Building vaccine trial capacity in Tanzania and Mozambique by continued support and training to laboratory personnel to explore the responses to DNA priming and MVA boosting strategies. Co-ordination of the grant and organisation of annual investigator meetings.</gtr:partnerContribution><gtr:piContribution>Intellectual input into design of epidemiological studies preceding the trial, design of the trial, data management, analysis plan, CRF, drafting of protocol. Responsibility for coordination of monthly oversight, review of safety, overseeing the monitoring of clinical sites. Participation in annual investigator meetings.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Imperial College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Imperial Clinical Trials Unit (ICTU)</gtr:department><gtr:description>AfreVacc I</gtr:description><gtr:id>36F61819-86C7-4AAA-9DFC-4E549DE8BE13</gtr:id><gtr:impact>Protocols approved for feasibility studies in South Africa, Mozambique and Tanzania. Contribution to creation of free access on line database for centralised data capture. Harmonisation of AfreVacc and TamoVac and UKHVC networks in order to add a gp140 protein boost to existing regimen of DNA and MVA in TaMoVac 01 trial.
AfrEVac trial was conducted as an amendment to TaMoVac 01 contributing a recombinant protein boost to participants already primed with DNA/MVA. this was the first time the three HIV immunogens were combined and the strategy is one that we hope to test for efficacy, subject to funding.</gtr:impact><gtr:outcomeId>UyG589LxUWv-1</gtr:outcomeId><gtr:partnerContribution>Logistical and project management, Co-ordination of monthly calls, Planning and organisation of annual investigator meetings, Collation of 6 monthly and annual reports. Co-ordination of training, Integration of other networks, submission of applications for no cost extension</gtr:partnerContribution><gtr:piContribution>Significant intellectual input into the establishment of a new network devoted to HIV vaccine development in the South harnessing the best methodologies and using constructs developed and taken to Phase I/II trials in Europe by the EuroVacc foundation, Significant intellectual input into builiding vaccine trial capacity in South Africa, Tanzania and Mozambique initially by purusing feasibility studies in at risk populations, sharing of exisiting data and expertise in the drafting of protocols and relevant documentation, contributions to design of clinical trials and studies, provision of appropriate training in all aspects of trial design and management, overall responsibility for the management of the trial and drafting of relevant documentation</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>UK HIV Vaccine Consortium (UKHVC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>MucoVac 2</gtr:description><gtr:id>F4694755-B04F-4DF4-9025-E6DCA3960040</gtr:id><gtr:impact>Trial protocol, CRF and database. 
Clinical study report.
Paper in presentation.</gtr:impact><gtr:outcomeId>kJqZu4bRLi7-3</gtr:outcomeId><gtr:partnerContribution>Provision of Clinical and laboratory facilities/staff for clincial trial. Responsibility for drafting reports and manuscripts. Trial sponsorship (SGUL) Coordination of drafting of trial protocol. Logistical and administrative support. Provision of product and collation of investigator brochure. Collation of submission to MHRA. Immunological analyses (Imperial).</gtr:partnerContribution><gtr:piContribution>Design of clinical trial, CRF, database and supporting documentation. Significant intellectual input into the drafting of the protocol. Co-ordination of networking between UKHVC (product), Helpmakehistory (volunteers). Responsibility for design of monitoring plan, monitoring of trial and preparation of relevant reports. Development of analysis plan and conducting analyses. Co-ordination of final report. Co-ordination of trial management.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Institute of Health, Mozambique (Instituto Nacional de Sa?de)</gtr:collaboratingOrganisation><gtr:country>Mozambique, Republic of</gtr:country><gtr:description>CutHivac</gtr:description><gtr:id>CF0ACB08-7315-4030-BEAD-A068255C50D8</gtr:id><gtr:impact>CutHivac001 a Phase I trial exploring the use of a novel mode of (prophylactic) vaccination in healthy volunteers fully enrolled (30 participants) in 2014, complete in 2015 and reported at two conferences: BHIVA 2016 and R4P 2016. Manuscript ready for submission.
CUHTHIVTHER a Phase II HIV therapeutic vaccine trial exploring different routes for delivering a DNA vaccine including transcutaneous and intramuscular with electroporation. 
Fully enrolled (30 participants) and completed in 2016. Clinical Study Report submitted to Sponsor, immunology complete and manuscript in draft.
CutHivac002 trials a Phase I prophylactic HIV vaccine trial exploring combination regimens with electroporation is underway and expected to complete in 2017.</gtr:impact><gtr:outcomeId>Lj9jG3qYyqz-6</gtr:outcomeId><gtr:partnerContribution>Co-ordination of the network activities via regular TC and annual investigator meetings. Collation of interim and annual reports. Integration of workpackages.</gtr:partnerContribution><gtr:piContribution>Responsibility for design of trial, analysis plan, drafting of protocol, harmonisation of data generated from other trials within network.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Royal Holloway, University of London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>UK HIV Vaccine Consortium</gtr:description><gtr:id>27311A32-4C6D-4018-86A1-4365B0B31926</gtr:id><gtr:impact>GMP material for clinical trials manufactured and procured with due diligence on intellectual property.
Annual UK HIV vaccine scientist meeting to review progress and comment on proposals, including meeting in March 2015 to determine whether or not to proceed to efficacy testing of current products.
Several clinical trials that were being conducted in our networks were provided partial support that facilitated completion and full analyses including CUTHIVAC and TaMoVac trials.</gtr:impact><gtr:outcomeId>hVGxkdxs6Zn-3</gtr:outcomeId><gtr:partnerContribution>Intellectual contributions to the design of trials, oversight and provision of GMP and supporting documentation such as the Investigator Brochure, provision of clinical facilities and expert personnel to conduct Phase I HIV vaccine trials, central coordination of the administrative aspects of the award.</gtr:partnerContribution><gtr:piContribution>Design including sample size rationale, drafting complementary grant applications, protocols, CRFs, trial documentation including analysis plan and submissions to competent authority, designing the central database, extracting and analysing data, preparing reports including the final Clinical Study Report.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Lausanne University Hospital  (CHUV)</gtr:collaboratingOrganisation><gtr:country>Switzerland, Swiss Confederation</gtr:country><gtr:description>EV03</gtr:description><gtr:id>FA910989-28A8-4D95-8861-87230F7EFCB9</gtr:id><gtr:impact>Presentation of results at international meetings (CROI, AIDS vaccine 2010, 2013). 
Final study report. 
Paper in preparation.</gtr:impact><gtr:outcomeId>caH6TbQ2odq-6</gtr:outcomeId><gtr:partnerContribution>Eurovacc co-sponsored this Phase IIa trial with ANRS.
IMPD (Eurovacc). Provision of NYVAC C (Eurovacc). Provision of DNA (University of Regensburg). Input into analysis (INSERM). Immunological assays (CHUV &amp;amp; ANRS).</gtr:partnerContribution><gtr:piContribution>Significant intellectual input into design of protocol, CRF, database, supporting documentation, analysis plan and monitoring plan. Co-ordination of trial management and responsibility for cross site monitoring. Analysis of data.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>King's College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Europrise</gtr:description><gtr:id>3F1F40F5-D901-4885-BA83-28E4C0D3C129</gtr:id><gtr:impact>Publications in peer reviewed journals, collation (and publication) of webbased toolkit to support product development from bench to bedside, facilitation of networking across other projects, dissemination, statistical support.</gtr:impact><gtr:outcomeId>KBMd6icniRs-9</gtr:outcomeId><gtr:partnerContribution>Co-ordination of project, collation of reports, organisation of annual network meetings, facilitation of networking, organisation of training/workshops.</gtr:partnerContribution><gtr:piContribution>Co-ordination and administration of workpackage dedicated to translational clinical activities. Contribution to Dissemination and Advocacy workpage also.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Verona</gtr:collaboratingOrganisation><gtr:country>Italy, Italian Republic</gtr:country><gtr:description>Europrise</gtr:description><gtr:id>D1E9B29C-516C-4825-B3FE-8D5C21DD78F9</gtr:id><gtr:impact>Publications in peer reviewed journals, collation (and publication) of webbased toolkit to support product development from bench to bedside, facilitation of networking across other projects, dissemination, statistical support.</gtr:impact><gtr:outcomeId>KBMd6icniRs-12</gtr:outcomeId><gtr:partnerContribution>Co-ordination of project, collation of reports, organisation of annual network meetings, facilitation of networking, organisation of training/workshops.</gtr:partnerContribution><gtr:piContribution>Co-ordination and administration of workpackage dedicated to translational clinical activities. Contribution to Dissemination and Advocacy workpage also.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Presentation at the UK HIV Community Advisory Board meeting</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>8F24EBE8-5EC9-4C93-BAE4-C133F0F023C3</gtr:id><gtr:impact>approx 50 advocates attended an all day meeting. Presentation &amp;quot;why is it so difficult to find an effective HIV vaccine&amp;quot; followed by an introduction to the Help make History website for healthy HIV vaccine trial volunteers

Interest shown in helping develop future studies</gtr:impact><gtr:outcomeId>GV3oSExukV5</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Prof. Robin Shattock presented at the All-Party Parliamentary Group meeting focussed on AIDS, TB and Malaria, 25th Feb 2014</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>B6C844A4-CE28-44FE-A348-BA80176B894D</gtr:id><gtr:impact>Professor Robin Shattock, Faculty of Medicine, Department of Medicine, Imperial College. Chairman of Mucosal infection and immunity and member of IAVI's Scientific Advisory Committee. Prof. Shattock addressed resistance to ARVs, therapeutic vaccines, the role of PrEP and the development of preventive vaccines.



Prof. Robin Shattock presented the challenges with resistance to ARVs which led on to discussions about why additional prevention options including microbicides and vaccines are needed. Slides on the UK HIV Resistance Database were presented also. Greater understanding gained by the APPG.</gtr:impact><gtr:outcomeId>5458c25eee5e30.02705724</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/parliamentarians</gtr:primaryAudience><gtr:url>http://www.lstmliverpool.ac.uk/events/february-2014/25-feb-all-party-parliamentary-group-on-malaria-and-neglected-tropical-diseases-meeting</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Media - Interview for article in The Guardian supplement The Scene: Help make history by volunteering for HIV vaccine clinical trials; published 2nd Aug 2014</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>7E6924AF-7604-46BA-897D-0F1A470D48AC</gtr:id><gtr:impact>Prof. Robbin Shattock interviewed, article created promoting recuitment to HIV vaccine trials.

Increase in requests for participation in Cuthivac 001 HIV vaccine trial, fully recruited as of 6th Nov 2014.</gtr:impact><gtr:outcomeId>54649703af00d1.46080310</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Satellite at AIDS vaccine 2012</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>8B71DD8A-0574-4666-83F3-BDC56EF5B387</gtr:id><gtr:impact>Talk invited for satellite meeting organised by Bill and Melinda Gates and EDCTP to provide feedback on AfreVacc / TaMoVac collaboration.

The talk at the EDCTP satellite was organised to inform their next round of funding.</gtr:impact><gtr:outcomeId>AMqdWYCHCup</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Paper Presentation</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>AfreVac Investigators meeting , Zanzibar</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>B8F5D751-2AB0-41E1-B300-2740ABC7091C</gtr:id><gtr:impact>The final annual meeting brought together all collaborators in the project to share final results and discuss publications.

Several publications are in preparation and valuable links were made between scientists from across the Tamovac and Afrevacc networks.</gtr:impact><gtr:outcomeId>oZ3ZQxSBqGi</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Paper Presentation</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2010,2011,2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Lecture to medical students at Guys and St Thomass</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>307D4DA9-4341-4AA8-85AE-EECBCA91A292</gtr:id><gtr:impact>I gave an overview of HIV vaccines to medical students, highlighting the work of the UKHVC

Course organiser invited Sarah Joseph to give lecture to medical students on HIV vaccines as part of their virology moduel.</gtr:impact><gtr:outcomeId>ivRYJrRTYuS</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Undergraduate students</gtr:primaryAudience><gtr:year>2012,2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Help Make History website www.helpmakehistory.mrc.ac.uk to increase interest in public participation in vaccine trials/information sharing</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>A7A4FEB0-CD63-4434-83BB-AB77C88545A9</gtr:id><gtr:impact>Increase in number of registrants to Help Make History database of potential participants to vaccine trials. Increase in number of direct enquiries relating to participation in vaccine trials.

Registration to the Help Make History database of potential participants to vaccine trials has increased, along with the number of direct enquiries. Cuthivac 001 trial is now fully enrolled (as of 6th Nov 2014) as as direct result of this engagement, along with profiling of vaccine recruitment on social media.</gtr:impact><gtr:outcomeId>545cbbb70d0884.85862836</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:url>http://www.helpmakehistory.mrc.ac.uk</gtr:url><gtr:year>2012,2013,2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Advocates Guide to the R4P Conference - webinar, 6th Nov. 2014</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>69696C4A-DA8D-4FAC-B388-E05C8266CE5E</gtr:id><gtr:impact>The webinar was organised to provide feedback on R4P Conference, the first international HIV prevention conference to bring vaccines, microbicides and PREP together. I was asked to speak specifically on the take home messages regarding prevention for gay men in Europe following the iPerGay and PROUD announcements. These two trials reported early due to interim analyses demonstrating that PrEP was highly effective in reducing the risk of HIV in an event driven regimen (iPerGay) and taking acccount of any change in risk behaviours (PROUD). 
There was also feedback regarding a number of Good Participatory Practice presentations after which I was able to make the point that Community Engagement has always been at the heart of preparing for large HIV prevention trials.

I was emailed after the webinar by researchers and Communtiy Advocates who agreed with the points I had made.</gtr:impact><gtr:outcomeId>545a6522d816a2.96754633</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Dr. Sue Fleck presented at a Careers Conference, University of East London, 2nd April 2014</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>A9744A05-15FF-437E-A622-834958E2C1E2</gtr:id><gtr:impact>Well attended presentation ~100 attendees. Lots of questions and an attentive audience.
Presentation title: Working for Research Funding Organisations, Job Opportunities for Science Graduates at the Medical Research Council (MRC) Clinical Trials Unit (CTU) @ University College London (UCL)


Requests for further information.</gtr:impact><gtr:outcomeId>5458c3d37a8251.18975860</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Undergraduate students</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Inaugural lecture</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>C5FE50C0-37D3-4FC7-8FA0-52B5B10B6220</gtr:id><gtr:impact>About 200 people from a range of disciplines and including the general public and school children attended and it was an opportunity to raise awareness of the ongoing HIV epidemic, the dramatic advances in biomedical interventions for the prevention of HIV and the importance of behaviour.

The lecture was videoed and posted on YouTube and tweeted.</gtr:impact><gtr:outcomeId>CCbPswDJyWf</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>EDCTP HIV Stakeholders meeting, Sep 2013</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>73358BA1-3A42-499C-928A-ECCF35F7894F</gtr:id><gtr:impact>There were about 100 delegates from Africa, Europe and the US that attended this meeting. The majority were senior and influential academics or from normative agencies.

I am uniquely privileged to be working in microbicides, vaccines and PrEP to reduce the risk of HIV, and across the spectrum of product development from Phase I through to implementation. This was a excellent opportunity to provide a perspective balanced by the breadth and depth of my clinical trial experience.</gtr:impact><gtr:outcomeId>LGPvQqb1UEn</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:url>http://www.edctp.org</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Dr. Sarah Joseph attendance at Symposium on therapeutic vaccines/activators of HIV eradication, 12th Dec 2013</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>14C66A46-1A75-451E-B336-6D245534AF96</gtr:id><gtr:impact>Discussion about therapeutic vaccines research priorities

Informed the design of the current and future research applications</gtr:impact><gtr:outcomeId>546497e2a3d769.90364847</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Dr Sarah Joseph invited to give a special lecture to third year medical studies on HIV vaccines at Kings College</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>7F4B3DF8-2300-4204-A399-EB7B9643C19A</gtr:id><gtr:impact>Talk sparked interest and discussion about HIV vaccines among students.

-</gtr:impact><gtr:outcomeId>5464af4cb8db94.76929784</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Undergraduate students</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Dr. Sarah Joseph attendance at Cuthivac annual Collaborators meeting, Nov 2013, Regensburg</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>07F2060E-16DB-41EC-B9F6-4B3F552AF98B</gtr:id><gtr:impact>Progress updates on Cuthivac Consortium workpages.

-</gtr:impact><gtr:outcomeId>5464ad5f2677f9.30224388</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>AIDS vaccine 2012 oral and poster presentations</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>1FCF827F-977C-408C-A900-0469B672DB50</gtr:id><gtr:impact>Audience of several thousand for the biggest international meeting about HIV vaccines. Posters were peer reviewed and 3 were selected for presentation.
website http://www.vaccineenterprise.org/conference/2012/

Priming with a &amp;quot;simplified regimen&amp;quot; of HIV-1 DNA vaccine is as good as a &amp;quot;standard regimen&amp;quot; when boosted with heterologous HIV-1 MVA vaccine in Tanzania. Patricia Munseri, Arne Kroidl, Charlotta Nilsson, Candida Moshiro, Said Aboud, Agricola Joachim, Christof Geldmacher, Eric Aris, Deus Buma, Eligius Lyamuya, Frances Gotch, Karina Godoy-Ramirez, Kisali Pallangyo, Leonard Maboko, Mary Marovich, Merlin Robb, Michael Hoelscher, Mohammed Janabi, Philipp Mann, Sarah Joseph, Sayoki Mfinanga, Wolfgang Stoehr, Fred Mhalu, Britta Wahren, Gunnel Biberfeld, Sheena McCormack, Eric Sandstrom, Muhammad Bakari


 
Preferential Targeting of Conserved Gag Regions After Vaccination with a Heterologous DNA Prime Modified Vaccinia Ankara Boost HIV Vaccine Regime. 
Asli Bauer , Lilli Podola , Antelmo Haule, Lwithio Sudi, Charlotta Nilsson, Philipp Mann, Marco Missanga, Bahati Kaluwa, Leonard Maboko, Cornelia Lueer, Maria Mwakatima, Said Aboud, Muhammad Bakari, Jeffrey Currier, Merlin Robb, Sarah Joseph, Sheena McCormack, Eligius Lyamuya, Britta Wahren, Eric Sandstr&amp;ouml;m, Gunnel Biberfeld, Michael Hoelscher, Arne Kroidl, Christof Geldmacher.

Antigen-specific T Lymphocyte Responses Elicited by a DNA - MVA HIV CN54gp140 Immunization Regime Are Significantly Altered by the TLR4 Adjuvant GLA. PF McKay, AV Cope, J Swales, S Joseph, M Esteban, R Tatoud, D Carter, J Weber, RJ Shattock




Useful links made with peers and also feedback provided for funders and policy makers who were also in attendance.</gtr:impact><gtr:outcomeId>DEMqJN6Vix8</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Poster Presentation</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Vaccine projects update at MRC CTU at Infections General Staff Meeting, 22nd Sept 2014</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>9A8A197E-E789-43CB-B363-159D2BCEE1B7</gtr:id><gtr:impact>Rosie Belcher presentation: Help Make History: A mixed methods descriptive study of factors affecting recruitment to phase I HIV vaccine trials
Sarah Joseph presentation: Vaccine trials update

Questions from the audience</gtr:impact><gtr:outcomeId>545ba466ecd990.44220344</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Use of Social Media for recruitment to HIV prevention research projects: Cuthivac 01 trial</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>F4A98556-033B-4D74-BE0F-D9D55A45FEE4</gtr:id><gtr:impact>Use of Twitter and Facebook for information sharing and to stimulate recruitment to the Cuthivac 01 vaccine study.

An increase in enquiries. Both studies now fully enrolled.</gtr:impact><gtr:outcomeId>5460e684b39833.17652083</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2013,2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>TaMoVac inestigators meeting, Zanzibar 2012, Mozambique 2013</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>414A8844-ADDE-48CC-B62F-7D4FBB05C99E</gtr:id><gtr:impact>This annual meeting is an opportunity for ~100 collaborators to share results and discuss progress of the multicentre project.

Volunteers from HIV vaccine trials attended this years meeting and were able to discuss their experiences with members of the team from different sites. The feedback from everyone was encouraging.</gtr:impact><gtr:outcomeId>Vmst7V8xBMq</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Paper Presentation</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2009,2010,2011,2012,2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>CUT'HIVAC annual investigators meeting</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>A7B90B25-FA4F-42D0-9797-6A2D22F5BF02</gtr:id><gtr:impact>Annual investigators meeting

Discussions during 2012 meeting led to discussions of design of new clinical trial which will be run in Peru.</gtr:impact><gtr:outcomeId>iGpGySchxjA</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Paper Presentation</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2010,2011,2012,2013</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>491380</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Clinical trial Collaboration - UKHVC</gtr:description><gtr:end>2016-03-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:fundingRef>083844</gtr:fundingRef><gtr:id>DB645646-5950-4AEB-B2DF-0556B8CB2D56</gtr:id><gtr:outcomeId>EfVL69aoBSD0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2008-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:department>Seventh Framework Programme (FP7)</gtr:department><gtr:description>TRANSVAC</gtr:description><gtr:end>2013-09-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:fundingRef>TNA1204-5 - HIV_vaccine_breakthrough</gtr:fundingRef><gtr:id>B7C292F3-EF8A-48A8-9BA6-60DA53ED332C</gtr:id><gtr:outcomeId>GE2MJ77R148</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2012-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>134664</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Network of Excellence</gtr:description><gtr:end>2011-12-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:fundingRef>037611</gtr:fundingRef><gtr:id>B3BB8486-5DB3-4557-BB09-CBC742F26CB6</gtr:id><gtr:outcomeId>joxftpFq56n0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>324810</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>CUTHIVAC (European Commission Collaborative Project - Large Scale Integrating Project)</gtr:description><gtr:end>2015-12-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:fundingRef>241904</gtr:fundingRef><gtr:id>7EC513D2-7CE7-4EDD-92D3-834455B26EEB</gtr:id><gtr:outcomeId>s7zYYS9aT8Q0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>66415</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>UKHIV Vaccine Consortium spoke 003 trial: MRC DCS scheme</gtr:description><gtr:end>2014-07-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>9746A01D-88B7-4EDC-AFEE-B814269F40C8</gtr:id><gtr:outcomeId>tf2HSkrw4tY</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>193790</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>European and Developing Countries Clinical Trials Partnership</gtr:department><gtr:description>Clinical Trial/capacity building - Afrevac</gtr:description><gtr:end>2012-03-02</gtr:end><gtr:fundingOrg>Sixth Framework Programme (FP6)</gtr:fundingOrg><gtr:fundingRef>CT.2006.33111.001</gtr:fundingRef><gtr:id>1E4EC9AE-BE9F-4CC0-A976-22B3DE96EDEE</gtr:id><gtr:outcomeId>FjtBuA4ue3j0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2008-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>450651</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>European and Developing Countries Clinical Trials Partnership</gtr:department><gtr:description>Clinical Trial/Capacity Building - Tamovac II</gtr:description><gtr:end>2014-11-02</gtr:end><gtr:fundingOrg>Sixth Framework Programme (FP6)</gtr:fundingOrg><gtr:fundingRef>IP.07.33112.001</gtr:fundingRef><gtr:id>5FF9CEE5-A10C-4F6D-B1FD-324C7EAB8EE0</gtr:id><gtr:outcomeId>omSoJ6Txhrw0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2009-11-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>CMO Seminar on future public health policy for HIV research</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>280FC47F-02C6-44F8-8A67-CCD63DC09697</gtr:id><gtr:impact>As a result of the seminar the CMO wrote to all GPs advising them to test patients presenting with glandular fever symptoms for HIV. The legalisation of self-testing was also raised and subsequently the CMO announced that the law would be changed from April 2014.</gtr:impact><gtr:outcomeId>nm2cFyDZQkt</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Consultation on Standards of Care in HIV prevention trials</gtr:description><gtr:geographicReach>Africa</gtr:geographicReach><gtr:id>4FA4D48F-D46B-4AA5-8E85-BD0FAB5FF926</gtr:id><gtr:outcomeId>hXiihyQweUw</gtr:outcomeId><gtr:type>Participation in a advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Dr. Sarah Joseph attendance at meeting: Vaccine-Induced Sero-Positivity/Sero-Reactivity (VISP/SR) meeting, Bethesda, USA 14-15 March 2013</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>B2E15A3A-EA24-421A-A65F-13674DC290D4</gtr:id><gtr:impact>Health providers made aware of the impact of HIV vaccines on HIV test results with an increase in the risk of vaccine associated positive results</gtr:impact><gtr:outcomeId>54649d7f0509c9.53141274</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type><gtr:url>http://www.vaccineenterprise.org/content/timely-topic-VISP</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Europrise Steering Committee</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:id>09757CE8-93DE-49DD-836B-1C65CB73F6E1</gtr:id><gtr:outcomeId>AhdQK7jo7SR</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>WHO/UNAIDS ethical conduct of HIV prevention trials guidelines</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>0AA190AD-5360-4708-97A0-5468F8940EB3</gtr:id><gtr:impact>The updated guidelines have been disseminated to research groups internationally and have influenced the dialogue between researchers and communities, facilitating joint ownership of large research projects even in resource limited settings.</gtr:impact><gtr:outcomeId>aQsobUypndU</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Good Participatory Practice Guidelines: case studies</gtr:description><gtr:geographicReach>Africa</gtr:geographicReach><gtr:id>6FF4918B-A86D-429A-AFE7-BD93BBC2950D</gtr:id><gtr:impact>Shared to research staff as lessons to improve implementation of GPP</gtr:impact><gtr:outcomeId>FZdEeAwnmam</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type><gtr:url>http://www.avac.org/implementation-tools</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>House of Lords Select Committee chaired by Lord Fowler</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>4DA9D86D-C20B-410E-BB40-E5917B786679</gtr:id><gtr:impact>Following this consultation home testing for HIV was became legal (April 2014)</gtr:impact><gtr:outcomeId>AERENfstqK2</gtr:outcomeId><gtr:type>Gave evidence to a government review</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Entry in the EDCTP Annual Report 2013 (published June 2014)</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>21F52C39-A40C-425C-ADFF-9E962753B989</gtr:id><gtr:impact>The MDP301 project which EDCTP co-funded was chosen as an example of good practice. EDCTP funding allowed microbicides to be introduced into Mozambique for the first time, with training of clinicians and researchers largely undertaken by the team from the University of Witswatersrand in Johannesburg.</gtr:impact><gtr:outcomeId>5464a1e9db3395.86076221</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type><gtr:url>http://www.edctp.org/annualreport2013</gtr:url></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>Full title: 'A randomised phase I/II study to assess the safety and immunogenicity of the DNA-GTU vaccine administered by two novel methods compared to placebo in HIV-infected patients on antiretroviral therapy.'

Vaccine administered trancutaneously or through electroporation (enhanced intramuscular delivery).

Trial participants: 30 HIV infected male and female volunteers aged 18-45 years who have been on ART for at least 6 months with 2 or more HIV plasma viral load measurements; 50 copies HIV RNA/ml prior to enrolment.

Funding provided through the European Commission CUTHIVAC grant.</gtr:description><gtr:id>4E7CB447-6B79-478C-9C43-D247A8C25278</gtr:id><gtr:impact>Analysis still to be done, trial fully recruited and participants in follow up.</gtr:impact><gtr:outcomeId>56defd650c25e0.48486784</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>CutHIVTher trial</gtr:title><gtr:type>Therapeutic Intervention - Vaccines</gtr:type><gtr:url>http://www.hra.nhs.uk/news/research-summaries/cuthivther-001/</gtr:url><gtr:yearDevCompleted>2015</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>DNA plasmid dervied from clade C CN54 which has been through Phase I and IIa trials. Significant benefit was gained from three primes (reported at CROI Feb10).</gtr:description><gtr:id>6DE895CA-27B6-4AB5-A538-67C296E98E4B</gtr:id><gtr:impact>Benefits of third DNA demonstrated in terms of broader and stronger immune responses.</gtr:impact><gtr:outcomeId>s7C5ySbmwPZ</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>DNA HIV CN54 prime followed by NYVAC C boost</gtr:title><gtr:type>Preventative Intervention - Nutrition and Chemoprevention</gtr:type><gtr:yearDevCompleted>2009</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>Clade C DNA
Clade C MVA
Clade C rgp140
GLA</gtr:description><gtr:id>3DC6CE56-17B2-42ED-8583-4C7A8680A7AE</gtr:id><gtr:impact>Completion of healthy volunteer HIV vaccine trial, evaluating products developed through the Wellcome Trust funded UK HVC.</gtr:impact><gtr:outcomeId>56ddcbbbc99cb0.38657098</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Actively seeking support</gtr:status><gtr:title>UK HVC Spoke3</gtr:title><gtr:type>Therapeutic Intervention - Vaccines</gtr:type><gtr:url>http://public.ukcrn.org.uk/search/StudyDetail.aspx?StudyID=14173</gtr:url><gtr:yearDevCompleted>2015</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>Full title: 'A phase I clinical trial to assess the safety and immunogenicity of three HIV GTU MultiHIV DNA immunisations administered via the Intramuscular, Intradermal and Transcutanous routes in healthy male and female volunteers.

Trial participants: 30 male and female volunteers aged 18-45 years old who are at low risk of HIV infection.

Funding provided through the European Commission CUTHIVAC grant.</gtr:description><gtr:id>716D6545-5E7F-4EED-B122-B646ED835CDB</gtr:id><gtr:impact>Participants meeting took place January 2016.
Analysis ongoing.</gtr:impact><gtr:outcomeId>56defb873a1f25.69463297</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>CutHIVac 001 trial</gtr:title><gtr:type>Preventative Intervention - Nutrition and Chemoprevention</gtr:type><gtr:url>http://public.ukcrn.org.uk/search/StudyDetail.aspx?StudyID=14858</gtr:url><gtr:yearDevCompleted>2016</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs><gtr:researchDatabaseAndModelOutput><gtr:description>HIV vaccine trial database</gtr:description><gtr:id>3C672F79-E11C-4BC9-9C83-C279AAB89F46</gtr:id><gtr:impact>Generation of reports for safety monitoring by the Trial Management Group and Independent Data Monitoring Committee</gtr:impact><gtr:outcomeId>56e011c66d1c00.88241876</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Cuthivac 002 study database</gtr:title><gtr:type>Database/Collection of data</gtr:type></gtr:researchDatabaseAndModelOutput><gtr:researchDatabaseAndModelOutput><gtr:description>This was one of the first study databases created using our in-house software CACTUS.</gtr:description><gtr:id>7BC20DD7-74D0-45BA-A49D-004D1F89B013</gtr:id><gtr:impact>CACTUS was developed in order to have control over development and change without dependencies on external contractors, and with resource limited settings in mind. The existence of the programmes that support the vaccine trial database will streamline implementation of vaccine trials in future.</gtr:impact><gtr:outcomeId>5462607f7f8329.30968472</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>MucoVac 2 study database</gtr:title><gtr:type>Database/Collection of data</gtr:type></gtr:researchDatabaseAndModelOutput><gtr:researchDatabaseAndModelOutput><gtr:description>Therapeutic vaccine trial database.</gtr:description><gtr:id>7BAE96FB-1ABC-46BC-A98D-F2A204F4E172</gtr:id><gtr:impact>Generation of reports for safety monitoring by the Trial Management Group and Independent Data Monitoring Committee</gtr:impact><gtr:outcomeId>56ddc9495110f6.29607228</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>CUTHIVTHER study database</gtr:title><gtr:type>Database/Collection of data</gtr:type></gtr:researchDatabaseAndModelOutput></gtr:researchDatabaseAndModelOutputs><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Protocol and case record forms to support a Phase I trial of a candidate HIV vaccine regimen comparing DNA prime and NYVAC boost to NYVAC alone.</gtr:description><gtr:id>37B9503D-C175-4602-81D9-E7E5A96AA031</gtr:id><gtr:impact>Provided to the HIVIS group which enabled them to implement their own DNA/MVA trial in Sweden and later in participants in Tanzania in collaboration with MUHAS</gtr:impact><gtr:outcomeId>NqJTdbZaabn</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>EV02 protocol and case record forms</gtr:title><gtr:type>Biological samples</gtr:type><gtr:yearFirstProvided>2006</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Technology transfer between Imperial College and collaborating institutions within Tanzania (MUHAS, MMRC). Training was carried out involving members of the Imperial and MRC teams.</gtr:description><gtr:id>99048935-9CC4-46B5-A7AC-A2481D2B99BE</gtr:id><gtr:impact>The assay will allow the quantitative assessment of an important endpoint in several trials using common reagents and so direct comparison of results across trials which would be extremely valuable.</gtr:impact><gtr:outcomeId>HCHKvf2uGUC</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Quantitative assay for the measurement of binding antibodies against CN54rgp140</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Report of Phase IIa trial of 3xDNA/1xNYVAC compared to 2xDNA/2xNYVAC that demonstrated benefit of third DNA prime.</gtr:description><gtr:id>811F27CF-0CCE-4CA9-8796-E271FC90E373</gtr:id><gtr:impact>Trials continue with 3xDNA priming</gtr:impact><gtr:outcomeId>YBUPY9fuopM</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>EV03 Clinical Study Report</gtr:title><gtr:type>Improvements to research infrastructure</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>The protocol which had been developed for a Phase I clinical trial running in London has been shared with another team within the CUTHIVAC consortium who are planning a trial using the same routes of vaccination in Peru.</gtr:description><gtr:id>2EEE87CF-1BB0-4087-8EF2-404BA28DBCCE</gtr:id><gtr:impact>The protocol relates to a clinical trial in healthy humans.</gtr:impact><gtr:outcomeId>FMpiXTSKetg</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Protocol for the CUTHIVAC preventative trial CUTHIVAC_001</gtr:title><gtr:type>Improvements to research infrastructure</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Final Clinical Study Report of the EV02 trial of DNA/NYVAC compared to DNA</gtr:description><gtr:id>E4CCFEC0-CC0B-4FFE-85DF-175A1DBF1F03</gtr:id><gtr:impact>Established the value of DNA priming</gtr:impact><gtr:outcomeId>PDyrw1LBQ7N</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>EV02 Clinical Study Report</gtr:title><gtr:type>Biological samples</gtr:type><gtr:yearFirstProvided>2008</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>The contents of a Clinical Study Report are defined in the International Conference on Harmonisation of technical reports E3 guideline. The report summarises the rationale, design, safety and efficacy data collected, data and trial management structures, as well as the primary and secondary analyses and a line listing of all adverse events that occured during the trial.</gtr:description><gtr:id>C0B7D953-286D-4ED5-8D77-16EB2ED72CAB</gtr:id><gtr:impact>Providing the report has helped other groups to draft their reports.</gtr:impact><gtr:outcomeId>5462506b85fb94.72047592</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>MucoVac2 Clinical Study Report</gtr:title><gtr:type>Improvements to research infrastructure</gtr:type><gtr:yearFirstProvided>2014</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>AFCB3608-E332-4164-A551-AF7F581B68F0</gtr:id><gtr:title>Glucopyranosyl lipid A adjuvant significantly enhances HIV specific T and B cell responses elicited by a DNA-MVA-protein vaccine regimen.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a28d6b1b37d4662bdc279f558e55c7c0"><gtr:id>a28d6b1b37d4662bdc279f558e55c7c0</gtr:id><gtr:otherNames>McKay PF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>545cd1947092c4.19680130</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7650BCF1-6FF4-49FE-9639-0E52E115C1E0</gtr:id><gtr:title>The challenge of defining standards of prevention in HIV prevention trials.</gtr:title><gtr:parentPublicationTitle>Journal of medical ethics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/860d34ad7a9af5b0d4cc8ad1aff097d7"><gtr:id>860d34ad7a9af5b0d4cc8ad1aff097d7</gtr:id><gtr:otherNames>Philpott S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0306-6800</gtr:issn><gtr:outcomeId>pm_14129_29_21186207</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E61721CA-14CC-4FB0-B7EE-F77F8A119A22</gtr:id><gtr:title>EV02: a Phase I trial to compare the safety and immunogenicity of HIV DNA-C prime-NYVAC-C boost to NYVAC-C alone.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ba7304cedf2514ac5d61b9eba0e13eb7"><gtr:id>ba7304cedf2514ac5d61b9eba0e13eb7</gtr:id><gtr:otherNames>McCormack S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn><gtr:outcomeId>qcu8yp8yud6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5EE8A6B0-104C-4013-9B53-65E3ECDC81B8</gtr:id><gtr:title>An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses.</gtr:title><gtr:parentPublicationTitle>The Journal of experimental medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b69f6ff98dbbad3733f17f652bff9864"><gtr:id>b69f6ff98dbbad3733f17f652bff9864</gtr:id><gtr:otherNames>Harari A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0022-1007</gtr:issn><gtr:outcomeId>jBxsvBBxStv</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D61BC261-1687-4556-BC23-11537AF534B1</gtr:id><gtr:title>Combined skin and muscle vaccination differentially impact the quality of effector T cell functions: the CUTHIVAC-001 randomized trial.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/88fde26ece5ca0b0fdddf21ca021e6fd"><gtr:id>88fde26ece5ca0b0fdddf21ca021e6fd</gtr:id><gtr:otherNames>Haidari G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>5a8bdd05cc6593.42599168</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>41FDBCE4-2C19-4D7C-A101-B922398C162C</gtr:id><gtr:title>Lessons from IAVI-006, a phase I clinical trial to evaluate the safety and immunogenicity of the pTHr.HIVA DNA and MVA.HIVA vaccines in a prime-boost strategy to induce HIV-1 specific T-cell responses in healthy volunteers.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b709ad3b8e7698295cad3772f08cf235"><gtr:id>b709ad3b8e7698295cad3772f08cf235</gtr:id><gtr:otherNames>Guimar?es-Walker A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn><gtr:outcomeId>taJnuCSi1pa</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>11D9E1D1-9C58-4F32-9756-6F83AE085397</gtr:id><gtr:title>Comparative Immunogenicity of HIV-1 gp140 Vaccine Delivered by Parenteral, and Mucosal Routes in Female Volunteers; MUCOVAC2, A Randomized Two Centre Study.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/854ceba29685db98d5f6eae1b410a101"><gtr:id>854ceba29685db98d5f6eae1b410a101</gtr:id><gtr:otherNames>Cosgrove CA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>5899f05e8b7896.84526131</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BF9F4C4A-64F7-43C7-9468-C679C4D20BCD</gtr:id><gtr:title>poster: What are the best methods to recruit healthy volunteers into HIV vaccine trials?</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/67bb48fefeaa37bfbb0c929b44097427"><gtr:id>67bb48fefeaa37bfbb0c929b44097427</gtr:id><gtr:otherNames>Jones CB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>545ba965ee9d25.38275916</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>76FAF535-84DD-4A51-861B-8F444516B731</gtr:id><gtr:title>Apples and oranges? Interpreting success in HIV prevention trials.</gtr:title><gtr:parentPublicationTitle>Contraception</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/11bddd801cf2dc93a2c908bfb499a765"><gtr:id>11bddd801cf2dc93a2c908bfb499a765</gtr:id><gtr:otherNames>Heise LL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0010-7824</gtr:issn><gtr:outcomeId>ReYMdocZGG6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>03F0DF83-0EEA-4D19-A81D-CB847F908986</gtr:id><gtr:title>Phase I HIV Vaccine Trial to Assess Safety and Immunogenicity of DNA Priming and MVA Boosting in Healthy Mozambican Young Adults</gtr:title><gtr:parentPublicationTitle>AIDS Research and Human Retroviruses</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/42b681c7c91dd5824379ba4c522a4c0a"><gtr:id>42b681c7c91dd5824379ba4c522a4c0a</gtr:id><gtr:otherNames>Viegas E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>545cd529d00691.99126576</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>582C19D3-8BF0-4741-9000-93E6241173CE</gtr:id><gtr:title>Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteers.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a8af3eae12e9c3485ab2e2ff801c5b9f"><gtr:id>a8af3eae12e9c3485ab2e2ff801c5b9f</gtr:id><gtr:otherNames>Cebere I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn><gtr:outcomeId>RhmxD8z2tjK</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9DE75DC6-915E-49A3-81B3-84BA69CB192F</gtr:id><gtr:title>A Comparative Phase I Study of Combination, Homologous Subtype-C DNA, MVA, and Env gp140 Protein/Adjuvant HIV Vaccines in Two Immunization Regimes.</gtr:title><gtr:parentPublicationTitle>Frontiers in immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7c886ea6a1f8c575a3e82ba71366caa9"><gtr:id>7c886ea6a1f8c575a3e82ba71366caa9</gtr:id><gtr:otherNames>Joseph S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1664-3224</gtr:issn><gtr:outcomeId>58bfdda6c75267.92313574</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D1B0FA31-481D-491E-94E2-7FFFA65F0B6B</gtr:id><gtr:title>Boosting with Subtype C CN54rgp140 Protein Adjuvanted with Glucopyranosyl Lipid Adjuvant after Priming with HIV-DNA and HIV-MVA Is Safe and Enhances Immune Responses: A Phase I Trial.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/969b8cc7367260e439f81e44a643a9c9"><gtr:id>969b8cc7367260e439f81e44a643a9c9</gtr:id><gtr:otherNames>Joachim A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>5899f05e5e03d6.70330009</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CB43639C-47DD-47F6-8936-53381FD6FA85</gtr:id><gtr:title>Diagnosing severe falciparum malaria in parasitaemic African children: a prospective evaluation of plasma PfHRP2 measurement.</gtr:title><gtr:parentPublicationTitle>PLoS medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/183540d8c4044e7bbfa1702b297b7cf5"><gtr:id>183540d8c4044e7bbfa1702b297b7cf5</gtr:id><gtr:otherNames>Hendriksen IC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1549-1277</gtr:issn><gtr:outcomeId>pm_14129_29_22927801</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6AD38E7A-7CEB-4D42-B668-8A678C47B3A0</gtr:id><gtr:title>Preferential Targeting of Conserved Gag Regions after Vaccination with a Heterologous DNA Prime-Modified Vaccinia Virus Ankara Boost HIV-1 Vaccine Regimen.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1990e5c332a8249728aca601b86ab34f"><gtr:id>1990e5c332a8249728aca601b86ab34f</gtr:id><gtr:otherNames>Bauer A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>5a8bdd05a69604.39136072</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BAD1EE4F-5BD3-4B32-93CD-0447610D5AC3</gtr:id><gtr:title>Ethical considerations in determining standard of prevention packages for HIV prevention trials: examining PrEP.</gtr:title><gtr:parentPublicationTitle>Developing world bioethics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2d1bb197cc904bb6e54a57f5b78db9ae"><gtr:id>2d1bb197cc904bb6e54a57f5b78db9ae</gtr:id><gtr:otherNames>Haire B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1471-8731</gtr:issn><gtr:outcomeId>pm_14129_29_23725227</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>03ED3314-B33E-4EF1-B93E-84841E08D1E4</gtr:id><gtr:title>Immune Responses after Two Immunizations with rgp140/GLA Following Priming with HIV-DNA and HIV-MVA in Healthy Tanzanian Volunteers</gtr:title><gtr:parentPublicationTitle>AIDS Research and Human Retroviruses</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/969b8cc7367260e439f81e44a643a9c9"><gtr:id>969b8cc7367260e439f81e44a643a9c9</gtr:id><gtr:otherNames>Joachim A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>545cd407d71501.59247717</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6AF57490-281E-475F-9CCD-2916249029C1</gtr:id><gtr:title>EV01: a phase I trial in healthy HIV negative volunteers to evaluate a clade C HIV vaccine, NYVAC-C undertaken by the EuroVacc Consortium.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/313df0512e24e9ea2ef86a625e0742b8"><gtr:id>313df0512e24e9ea2ef86a625e0742b8</gtr:id><gtr:otherNames>Bart PA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn><gtr:outcomeId>m6UkRrXL2nU</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EEF3A2BD-7FCD-4C27-A7A8-2A3FB90CE2A3</gtr:id><gtr:title>Priming with a simplified intradermal HIV-1 DNA vaccine regimen followed by boosting with recombinant HIV-1 MVA vaccine is safe and immunogenic: a phase IIa randomized clinical trial.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/90466e1d0187bb80b46c6a3a8f89dd07"><gtr:id>90466e1d0187bb80b46c6a3a8f89dd07</gtr:id><gtr:otherNames>Munseri PJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>56b1d55202b0e8.14154181</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_U122861400</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>8F896112-5A04-4A11-A9F0-2B446D9AAC8A</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>5.1  Pharmaceuticals</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>7135039D-2DB0-4D41-87B3-FA1C8D38E133</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>6.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>